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ABSTRACT 
Background: Social anxiety disorder (SAD) is a common psychiatric condition 
characterised by fear and avoidance of social situations. Lifetime prevalence is 5-
16% and co-morbidity with other mood and substance abuse disorders is common. 
Symptoms including cognitive, behavioural and physiological components vary 
between individuals. Of these, blushing and gaze fear and avoidance are regarded as 
cardinal symptoms. First line treatment of SAD involves SSRIs and cognitive 
behavioural therapy, while surgery may also be considered for excessive blushing. 
Blushing and gaze avoidance are thought to have an evolutionary adaptive 
advantage, promoting the display of submissive behaviour and appeasement in 
threatening situations. MRI research has demonstrated differences on functional and 
structural neuroimaging between patients with SAD and healthy controls (HCs). 
However, little is known about the neurocircuitry underlying gaze fear and 
avoidance or increased blushing propensity or how the severity of these traits 
correlate with the neuroimaging differences found in SAD. In this research, I 
explored the neuroanatomy of blushing propensity and gaze fear and avoidance in 
the context of SAD. 
Methods: 18 SAD patients and 18 HCs underwent structural MRI scans and self-
report scales were administered to assess their symptom severity, blushing 
propensity and gaze fear and avoidance. Structural data was analysed using voxel-
based morphometry (VBM). Regression and contrast analyses were used to correlate 
blushing propensity and gaze anxiety and avoidance symptoms with brain volumes, 
controlling for total grey matter volume, age and level of education.  
Results: Anxiety, blushing propensity and gaze fear and avoidance symptoms were 
all significantly higher in SAD patients (p<0.001). Brainstem volumes were 
increased for higher blushing scoresa (p<0.01), while the volumes of left inferior 
parietal lobeb (p=0.04) and left occipital cortexa (p<0.01) were decreased. With 
increased gaze fear and avoidance, there were associated decreases in the right 
posterior cingulate cortexa (p<0.01), right occipital lobeb (p=0.03) and right fusiform 
gyrusa (p<0.01). Increased blushing and gaze symptom severity considered together, 
was associated with increased brainstem volumea (p<0.01) and decreased 
pons/cerebellumb (p=0.001), right cerebellumb (p=0.009), left cerebellumc (p<0.001) 
and left inferior parietal lobea (p<0.1), volumes. Contrast analysis of SAD and HC 
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brain volumes revealed a greater grey matter volume in HCs in the regions of left 
occipital cortex (p<0.01), left anterior cingulate (p<0.01) and right inferior parietal 
lobe (p<0.01) when compared to SAD patients. Increased symptom severity in SAD 
was significantly associated with higher volumes in the left premotor cortex 
(p<0.01), right hippocampus (p<0.01), left orbitofrontal cortex (p<0.01) and right 
superior temporal cortex (p<0.01). Possible areas for of interest for volume 
differences between SAD and HCs include total grey matter volume (d=0.83), left 
and right anterior cingulate cortex (d=0.68 and d=0.65), and left and right 
dorsolateral prefrontal cortex (d=0.55 and d=0.54), yet these differences were not 
significantly different. (auncorrected peak levels buncorrected cluster level, ccorrected cluster 
level).  
 
Conclusion: Differences in brain volumes pertaining to blushing and gaze fear and 
avoidance in SAD patients may be a contributing factor or a consequence of these 
core symptoms, and a potential biomarker for SAD.  Future studies could build on 
this preliminary research with increased sample sizes, and determine the possible 
effects of reduced symptom severity and treatment options on brain structure and 
function. Most importantly, an investigation of the genetic underpinnings and 
functional neural correlates of blushing and gaze avoidance behaviour may enhance 
our understanding of the complex aetiology of these cardinal SAD symptoms, 
thereby improving our understanding of SAD as a psychiatric disorder and 
facilitating better patient care and management. 
 
Key words: social anxiety; social anxiety disorder; social phobia; gaze avoidance; 
gaze fear; gaze anxiety; blushing; fear of blushing; erythrophobia; blushing 
treatment; structural MRI; grey matter volume; voxel-based morphometry 
  
5 
 
TABLE OF CONTENTS 
 
ABBREVIATIONS .................................................................................................... 7 
ACKNOWLEDGEMENTS ....................................................................................... 8 
INTRODUCTION ...................................................................................................... 9 
Literature Search ...................................................................................................... 9 
Social Anxiety Disorder: Definition, Classification, and Epidemiology ................. 9 
Diagnosis of SAD .................................................................................................. 11 
Aetiology of SAD .................................................................................................. 11 
Adaptive function of blushing and gaze avoidance in social anxiety .................... 12 
Blushing .............................................................................................................. 14 
Gaze avoidance ................................................................................................... 16 
Neurobiology of SAD, gaze behaviour and blushing ............................................ 18 
Neurobiology of SAD ......................................................................................... 18 
Neurocircuitry of embarrassment and blushing .................................................. 22 
Neurocircuitry of gaze behaviour ....................................................................... 23 
Treatment of SAD, blushing and gaze avoidance .................................................. 24 
Treatment of SAD ............................................................................................... 25 
Treatment of blushing ......................................................................................... 26 
Treatment for gaze avoidance ............................................................................. 29 
Summary ................................................................................................................ 34 
AIMS AND OBJECTIVES ..................................................................................... 36 
METHODS ............................................................................................................... 37 
Participants ............................................................................................................. 37 
Materials ................................................................................................................. 38 
Structural MRI .................................................................................................... 38 
Administered Scales ........................................................................................... 38 
Procedure................................................................................................................ 40 
MRI Data analysis .................................................................................................. 41 
Statistical analysis of MRI and questionnaire data ................................................ 41 
RESULTS ................................................................................................................. 43 
Test of normality .................................................................................................... 43 
Administered Scale Scores ..................................................................................... 43 
Structural grey matter differences between participants with Social Anxiety 
Disorder and healthy controls ................................................................................ 46 
DISCUSSION ........................................................................................................... 62 
6 
 
Objective 1: Blushing propensity and gaze fear and avoidance symptoms in SAD
 ................................................................................................................................ 62 
Objective 2: Structural neurological differences in relation to blushing propensity 
and gaze fear and avoidance .................................................................................. 64 
Structural differences between SAD patients and HCs ...................................... 64 
Structural differences predicted by symptom severity, blushing propensity and 
gaze avoidance .................................................................................................... 67 
Further considerations ............................................................................................ 72 
Limitations ............................................................................................................. 74 
Recommendations for Future Research ................................................................. 76 
Conclusion ............................................................................................................. 77 
APPENDIX A ......................................................................................................... 101 
APPENDIX B ......................................................................................................... 105 
APPENDIX C ......................................................................................................... 106 
APPENDIX D ......................................................................................................... 109 
 
  
7 
 
ABBREVIATIONS 
The following abbreviations appear in this dissertation: 
 
ACC – anterior cingulate cortex 
BPS – blushing propensity scale 
CBT – cognitive behavioural therapy 
CS – compensatory sweating 
CSF – cerebrospinal fluid 
DLPFC – dorsolateral prefrontal cortex 
DMPFC – dorsomedial prefrontal cortex 
DSM – diagnostic and statistical manual of mental disorders 
ESB – endoscopic thoracic block 
ETS – endoscopic thoracic sympathectomy 
fMRI – functional magnetic resonance Imaging 
FWE – familywise error 
GARS – gaze anxiety rating scale 
HC – healthy control 
LSAS – Liebowitz social anxiety scale 
MNI – Montreal Neurological Institute  
MRI – magnetic resonance imaging 
MRS – magnetic resonance spectroscopy 
PET – positron emission tomography 
PRS – percutaneous radiofrequency sympathicolysis 
QOL – quality of life 
RC – rami communicantes 
RDoC – Research Domain Criteria 
SAD – social anxiety disorder 
SD – standard deviation 
SPM – statistical parametric mapping 
SSRI – selective serotonin reuptake inhibitor 
T1, T2, T3, T4 – first, second, third, fourth thoracic vertebra 
VBM – voxel-based morphometry  
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INTRODUCTION 
 
Social anxiety disorder (SAD) is a prevalent psychiatric disorder, characterized by 
fear of social situations.  Characteristic symptoms of SAD include blushing and gaze 
avoidance. The aim of this chapter is to review the literature on social anxiety, with a 
particular focus on blushing and gaze avoidance. There is growing information from 
animal studies and imaging research on the psychobiology of social anxiety, and this 
will be summarized.  At the same time, areas that have not yet been adequately 
explored will be highlighted, with the intention of further exploring them in this 
dissertation.  
 
Literature Search 
Articles for the literature review were obtained by searching the electronic journal 
databases of PubMed, Science Direct and Google Scholar. Relevant articles found 
using the search terms “social anxiety disorder” or “social phobia”, “blushing”,  
“gaze”, “MRI”, “blushing treatment”, and “social emotions” were reviewed. Other 
relevant articles were found through the references in the articles obtained from the 
search.  
 
Social Anxiety Disorder: Definition, Classification, and Epidemiology  
Social anxiety disorder (SAD), also referred to as Social Phobia (DSM-IV), is one of 
the six major anxiety disorders listed in the Diagnostic and Statistical Manual of 
Mental Disorder (DSM-V; APA, 2013). The disorder is characterised by “marked 
fear or anxiety about one or more social situations in which the individual is exposed 
to possible scrutiny by others” (DSM-V, p. 202). This fear may be limited to certain 
domains (e.g. public speaking) or may be generalized across many social situations 
(Muller, Koen, Seedat & Stein, 2005), usually with the generalised sub-type leading 
to worse symptoms and greater impairment (Brook & Schmidt, 2008). Everyday 
situations that are easily negotiated by many (e.g. eating or drinking while being 
observed by others, having a conversation, and meeting unfamiliar people) have the 
potential to provoke excessive anxiety in those with SAD, beyond what could be 
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considered normal shyness (den Boer, 1997). Symptoms consist of affective, 
cognitive, behavioural and physical components (Muller et al., 2005; Price, 2003). 
These may include panic responses (even full panic attacks in some cases), extreme 
situational avoidance, avoidance of eye contact, tension, stuttering, mumbling, nail 
biting, and a partial or complete range of somatic complaints, such as increased heart 
rate, sweating, shaking, trembling, and blushing (Albano, 1995; Beidel & Turner, 
2007). Self-conscious emotions and cognitive appraisals such as embarrassment, 
desire to escape, self-criticism, feelings of inadequacy and failure may accompany 
these experiences (Ollendick & Hirshfeld-Becker, 2002). Those with SAD 
experience significant impairment of functioning in social, academic and 
occupational domains (APA, 2013).   
 
After depression and alcohol abuse, this debilitating disorder is reportedly the third 
most common psychiatric diagnosis (Heimberg, Stein, Hiripi & Kessler, 2000; 
Schneier, 2006). Lifelong prevalence rates are high, between 5-16% in Western 
countries (Heimberg et al., 2000; Wittchen, Stein & Kessler, 1999) with a higher 
preponderance in females (ratio estimated between 1.5:1 and 2.5:1; Judd, 1994; 
Hidalgo, Barnett & Davidson, 2001; Rapee & Spence, 2004), although clinical 
samples often have even or reversed gender representation (Muller et al., 2005). The 
disorder may have its onset in childhood, but more commonly begins during mid-
adolescence (Furmark, 2002; Seedat & Stein, 2007; Schneier, Johnson, Hornig, 
Liebowitz & Weissman, 1992). The course of SAD tends to be lifelong (den Boer, 
1997) and patients are more likely to have lower levels of education, remain 
unemployed, earn less, or remain single (Schneier et al., 1992). 
 
It is common for individuals with SAD to experience co-morbid psychiatric 
disorders (between 69-81% according to Fehm & Wittchen, 2004), including other 
anxiety disorders, substance abuse, major depressive disorder, bipolar disorder  and 
dysthymia (den Boer, 1997; Fava et al., 2000; Kessler, Stang, Wittchen, Stein & 
Walters, 1999; Merikangas & Angst, 1995; Merikangas, Angst, Eaton & Canino, 
1996; Merikangas et al., 2007). Of all the anxiety disorders, social anxiety disorder is 
thought to be the most likely to co-occur with mood disorders, often preceding a 
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mood disorder diagnosis (Fava et al., 2000; Pini et al., 2006). Patients may also self-
medicate with alcohol, which may contribute to explaining co-morbid substance 
abuse diagnoses. 
 
Diagnosis of SAD 
Evidence suggests that this chronic disorder is both under-diagnosed and under-
treated due to a combination of delayed presentation (due to avoidance of help-
seeking as a result of anxiety or lack of recognition of symptoms as diagnosable and 
treatable), lack of awareness or diagnostic clarity among primary care professionals, 
and the presence of co-morbid presentations (Katzelnick & Griest, 2001; Lydiard, 
2001). For a diagnosis to be made, the individual must suffer from persistent, 
marked and irrational fear or anxiety about one or more social situations, and either 
avoids these situations or suffers them with great anxiety (APA, 2013). Individuals 
fear that they will exhibit behaviour or symptoms that will lead to negative 
evaluation. The fear, anxiety or avoidance causes significant distress to the 
individual, interfering with functioning, and usually persists for at least 6 months. 
Other psychiatric differentials, medical conditions and drug related causes need to be 
excluded. 
 
Aetiology of SAD 
SAD is a psychiatric disorder encompassing multiple aetiological causes including 
genetic, hormonal, developmental, and environmental. The interaction between these 
various aetiological factors is complex, and any one factor is neither necessary nor 
sufficient to determine the development of the disorder (Ollendick & Hirshfeld-
Becker, 2002). The aetiology of SAD with reference to cognitive, affective and 
genetic components is discussed below, with the neural components discussed later.  
 
Transient, age-related anxiety behaviour is a normal part of human development 
(Ollendick & Hirshfeld-Becker, 2002). For example, stranger anxiety can be 
observed in infants as young as 6 months old (Rosenbaum, Biederman, Hirshfeld, 
Bolduc & Chaloff, 1991). This and other developmental phases of anxiety fade in 
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most cases. However, a minority may retain social anxiety and the consequent 
inhibited behaviour as they grow up, which increases the risk of SAD developing in 
these individuals (Rosenbaum et al., 1991; Ollendick & Hirshfeld-Becker, 2002).  
 
Cognitive behavioural models for the development of SAD suggest that there is an 
attentional bias and hypervigilance to internal negative cognitions, as well as 
external stimuli that are perceived to be threatening, leading to increased threat 
detection (Eysenck, 1992; Clark & Wells, 1995; Rapee & Heimberg, 1997). 
Individuals with SAD may have difficulty disengaging from perceived threat (Rapee 
& Heimberg, 1997) or exhibit increased avoidance behaviour (Clark & Wells, 1995). 
This is thought to play a role in maintaining the fear experienced by those with SAD.  
 
This disorder is partially heritable, occurring more commonly in first degree relatives 
than in the general population (Merikangas & Angst, 1995; Rosenbaum, Bierderman, 
Pollock & Hirshfeld, 1994).  Environmental factors may also play a role, including 
exposure to stressors early in life (Gabbard, 1992). Developmental theory suggests 
that individual temperamental, cognitive and genetic factors may interplay with 
environmental factors in the development of the disorder (Ollendick & Hirshfeld-
Becker, 2002). Such environmental factors include parental psychopathology and 
over-control, adverse life events, difficult interpersonal relationships, and cultural 
values (Brook & Schmidt, 2008). These environmental factors interacting with a 
genetic pre-disposition, may contribute to the development of SAD in an individual. 
 
Adaptive function of blushing and gaze avoidance in social anxiety 
Characteristic symptoms of SAD include exaggerated blushing propensity and gaze 
avoidance, including fear of making eye contact (Edelmann, 1990; Schneier, 
Rodenbaugh, Blanco, Lewin & Leibowitz, 2011). This is consistent with an 
evolutionary perspective which highlights the adaptive nature of anxiety, and social 
anxiety specifically.  
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In the environment inhabited by early mammals, dangerous situations arose with 
frequency, particularly in the event of perilous natural events (e.g. lightning strikes 
and falling objects), being hunted by a predator, being antagonised by conspecfics 
(Tooby & Cosmides, 1990). Thus, it was necessary for the development of defensive 
adaptations to escape and avoid such threats in order to survive and reproduce 
(Öhman & Mineka, 2001). These defensive mechanisms first required sensory 
perception and motor reflexes, followed by innate defence mechanisms, conditioned 
responses, and later developments of affective and cognitive states that allow for 
deliberation and decisions in response to threat (Razran, 1971). Fear, or anxiety, 
became a central driver of these responses. Anxiety, therefore, is a strong motivator 
for self-preservation through escape and avoidance of danger or conflict (Epstein, 
1972 as cited in Öhman & Mineka, 2001). The anxiety response (fight-or-flight, 
freezing, aggression etc.) may be much the same across a large variety of situations, 
because the same type of response may have yielded survival advantage across a 
variety of situations in the past (Price, 2003). While anxiety has adaptive advantages, 
excessive is likely to impact negatively on functioning, leading to disordered 
behaviour and may impede ability to effectively manage situations (Price, 2003).  
 
Individuals with SAD tend to avoid social interaction or display avoidance behaviour 
during social interactions, possibly due to fear of negative evaluation (APA, 2013; 
Bögels et al., 2010; Voncken, Rinck, Deckers & Lange, 2012). Individuals suffering 
from SAD often exhibit submissive behaviours during social encounters (Russell et 
al., 2011). Such “safety behaviours” are thought to perpetuate and maintain SAD in 
an individual (Clark, 2001; Hofmann, 2007; Rapee & Heimberg, 1997). These 
behaviours may be under voluntary control, or may happen on a subconscious, 
involuntary level. Consciously employed safety behaviours may include remaining 
silent, concealing physical anxiety symptoms with clothing (Cuming et al, 2009; 
Voncken et al., 2012). Automatic safety behaviours may include avoidance of eye-
contact and maintaining interpersonal distance (Foa and Kozak, 1986). Avoidance 
behaviours increase with the intensity of a social stressor (Roelofs, Elzinga & 
Rotteveel, 2005; Roelofs et al., 2009), and this has been corroborated by research on 
visual avoidance in non-social phobias (Aue, Hoeppli, Piguet, Sterpenich, & 
Vuilleumier, 2013; Tolin, Lohr, Lee & Sawchuk, 1999). 
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Blushing  
Blushing in SAD may also be regarded as a submissive behaviour that may serve an 
adaptive function, but may contribute to pathological cognitive and affective patterns 
in some individuals. Despite featuring as a component of this psychiatric disorder, 
blushing is generally regarded a universal emotional response (Leary, Britt, Cutlip, 
& Templeton, 1992). The universality of blushing hints at its evolutionary 
advantage. Darwin (1892/1904, p. 327) regarded it as the “most peculiar and most 
human of all expressions”.  
 
Facial blushing, caused by cutaneous blood vessel dilatation, is both a salient and 
rapidly developing response elicited by emotional stimuli (Drott, Claes, & Rex, 
2002). This response is mediated by the upper thoracic chain of sympathetic nervous 
system: the blush region is supplied with beta-adrenoreceptors, resulting in a dilator 
effect on the basal tone of the vasculature (Drummond, 1997; Mellander, Andersson, 
Afzelius, & Hellstrand, 1982). The blush region includes the face, forehead, neck, 
ears and sometimes the upper chest (Gerlach, Wilhelm, Gruber, & Roth, 2001). 
Blushing is socially produced, and is not to be confused with non-social reddening 
(flushing), caused by temperature changes, physical exertion or consumption of 
alcohol (Leary et al., 1992). Blushing may differ between individuals in frequency 
and intensity (across cultures and ages), and perceptibility (depending on skin 
darkness; Darwin 1982/1904).  
  
Face-to-face contact involving self-conscious emotions of embarrassment or shame 
is the predominant cause of blushing (Shields, Mallory, & Simon, 1990). Blushing 
very rarely occurs when not in the presence of others (Darwin 1982/1904). While 
blushing is thought to be a hallmark response to embarrassment (Buss, 1980 as cited 
in Edelmann & Skov, 1993), it is thought that it may also result more generally from 
social attention (Leary et al., 1992). However, blushing and embarrassment may 
commonly co-occur, given that embarrassment often results from unwanted social 
attention (Edelmann & Skov, 1993). Social situations that elicit blushing include 
threats to an individual’s public identity (through the violation of social norms), or 
undesired social attention from others (through scrutiny or positive attention and 
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praise). While embarrassment is usually brought about by an external event, it is 
possible that expressive cues (such as blushing) resulting from internal cognitive 
processes, may be enough to cause severe embarrassment (Edelmann, 1990; 1991). 
Thus, individuals, such as those with SAD, who are particularly sensitive to internal 
cues, may be more prone to blush and suffer from embarrassment. Indeed, chronic 
blushing is associated with high levels of social anxiety and self-consciousness 
(Endelman, 1990; 1991) as well as embarrassability (Leary & Meadows, 1991).  
 
Displaying embarrassment or shame may have instrumental value in social 
interactions, because it indicates that the individual recognises the social 
transgression that he or she has made and regrets having done so (Keltner & 
Buswell, 1997). This signal of admittance may effectively diffuse a threatening 
situation by appeasing the recipient or observer of the social transgression. Such 
displays in both human and non-human animals involve gaze aversion, smiling, 
displaying the neck and reducing physical size. This phylogenetic similarity 
indicates an evolutionary basis for human variants of appeasement. Thus, blushing, 
as a signal of embarrassment or shame, may function to appease conspecifics (Leary 
et al., 1992; Keltner, 1995). 
 
Despite its potential adaptive function, individuals often regard blushing as an 
undesirable response that they seek to prevent or conceal (de Jong & Peters, 2005; 
Shields et al., 1990). Some individuals experience distress due to blushing to the 
extent of becoming phobic and seeking treatment (Bögels, 2006; Gerlach et al., 
2001), and it has been noted that some patients with SAD develop a fear of blushing 
and increased blushing propensity (Bögels, 2006; Bögels & Stein, 2009; Bögels et 
al., 2010; Edelmann, 1990; Gerlach et al., 2001), and it has been included as a 
“hallmark physical response” of the disorder (APA, 2013, p. 204).  It has been 
argued that fear of blushing should be considered a specific sub-type of this disorder, 
where erythophobia (fear of blushing) is the primary complaint (Drott, 2004). 
Erythophobia is characterised by frequent episodes of severe blushing that are easily 
and instantly elicited, and are often associated with embarrassment and social 
incapacitation (Drott et al., 2002). Indeed, in research conducted in the Netherlands 
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(Bögels, 2006) and Japan (Matsunaga, Kiriike, Matsui, Iwasaki & Stein, 2001), over 
half of individuals with SAD report somatic complaints, such as blushing and 
sweating, as their largest fear.  
 
While SAD patients with a fear of blushing may subjectively perceive that they 
blush more readily than others, it is unclear whether they objectively blush more than 
those without the disorder. There is some evidence that individuals with SAD as well 
as blushing complaints, exhibit greater physiological blushing (measured by blood 
flow and cheek temperature compared to SAD individuals without blushing 
complaints (Voncken & Bögels, 2008). The intensity of the blush depends on the 
amount of stress experienced in the situation provoking the blush (Mulkens, de Jong, 
Dobbelaar, & Bögels, 1999). 
 
SAD patients without fear of blushing seem to have a reduced blush response, even 
compared to controls without SAD. However, these findings are not consistent 
across other studies, which found that there was no physiological difference in 
blushing between those who are fearful of blushing and those who are not (Mulkens, 
de Jong & Bögels, 1997; Mulkens et al., 1999). Instead, these studies found that 
severity of blushing was a subjective experience in blushing fearful individuals. 
Thus, it is unclear whether those SAD patients, who report increased blushing 
propensity or a fear of blushing, have an objectively increased blush response or not. 
 
Gaze avoidance 
Like blushing, gaze avoidance is considered to be a significant behavioural 
component of SAD (Schneier et al., 2011; Weeks, Howell & Goldin, 2013). This is 
thought to be problematic in SAD, because it impairs social interactions. Non-verbal 
visual communication is important in social, group-living animals, particularly 
primates (Emery, 2000). Communication via sustained eye contact is a behaviour 
readily employed by humans (Gilbert, 2001), and is normally used to facilitate social 
interactions, convey important emotional information, and moderate how one is 
perceived by others (Kleinke, 1986; Napieralski, Brooks & Droney, 1995; Öhman, 
Lundqvist & Esteves, 2001). Perception of, and attention to, faces, particularly the 
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eye area, is an important component of emotional and verbal communication 
(Gilbert, 2001; Öhman et al., 2001).  
 
Evolutionary theory further posits that the emotion of fear (discussed earlier as a 
conserved adaptation) ensures rapid focusing of attention on potential threats, with 
heavy reliance on attentional gaze (Öhman & Mineka, 2001). Direct gaze may signal 
attention from a threatening individual (e.g. predator), making gaze detection an 
evolutionary survival mechanism, often resulting in a fearful or submissive response 
(Emery, 2000; Gilbert, 2001). Gaze avoidance is a cross-species behaviour that 
indicates social submission and may have evolved as a defence against conflict 
(Öhman, 1986). In SAD, this mechanism results in a pattern of vigilance followed by 
avoidance, with increased attention to threat followed by increased avoidance of the 
threat.  
 
Research on the phenomenon of gaze avoidance has determined that individuals with 
SAD exhibit significantly less eye contact when engaging with others than do those 
without the disorder (Baker & Edelmann, 2002). Studies have used eye-tracking to 
determine eye contact patterns in individuals with SAD reacting to images of 
negative and positive faces (Horley, Williams, Gonsalves & Gordon, 2003; 2004; 
Moukheiber et al., 2010; Wieser, Pauli, Alpers & Muhlberger, 2009). These studies 
generally found that while most individuals with SAD tended to avoid eye contact 
more than healthy controls (HCs), increased symptom severity was associated with 
increased gaze avoidance and decreased fixation on the eye area of faces. Gaze 
avoidance has been found to be consistent across gender (Moukheiber et al., 2010) 
and increased for negative emotion (e.g. anger) directed at the observer through 
direct gaze (Lange et al., 2011; Roelofs et al., 2010). It is postulated that gaze 
avoidance plays a significant role in sustaining social anxiety disorder, by negatively 
reinforcing fearful responses (Greist, 1995; Marks & Gelder, 1969 as cited in 
Moukheiber et al., 2010; Öhman, 1986).  
 
Blushing and gaze in the context of SAD have been explored in the context of 
evolutionary adaptation, cognitive and affective mechanisms as well as their place in 
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the pathology of SAD. It seems clear that blushing is physiological response with 
complex social and psychological components. While the basic physiology of 
sympathetic stimulation and cutaneous vasodilatation of blushing is well-known, the 
precise mechanism is poorly understood. Furthermore, the regions of the brain 
involved in the blush response remain unexplored. Similarly, while gaze behaviour 
in SAD individuals has been investigated, only a handful of studies have conducted 
research into the neurobiological underpinnings of this trait. 
 
Neurobiology of SAD, gaze behaviour and blushing 
What is known of the neurobiological underpinnings of these cognitive, affective and 
behavioural components of SAD will now be discussed. There is evidence for 
alterations in brain structure, functional brain activation, and neurotransmitter 
systems in patients with SAD. However, less is known about the neurobiology of 
blushing and brain behaviour. 
 
Neurobiology of SAD 
Abnormalities in the basal emotional centres of the brain, detected in functional 
neuroimaging (fMRI) studies, have been implicated in SAD pathogenesis. Several 
fMRI studies suggest that individuals with the disorder may possess amygdala 
hyperactivity and an inability to engage the ventromedial frontal areas implicated in 
the regulation of emotions (Hattingh, 2011; Phan, Fitzgerald, Nathan & Tancer, 
2006; Shin & Liberzon, 2010; Stein, Goldin, Sareen, Zorrilla & Brown, 2002; 
Straube, Mentzel & Miltner, 2005). The amygdala has been implicated in early, 
reflexive detection of salient threat stimuli (LeDoux, 1998; Morris, Öhman & Dolan, 
1998; Schneier, Kent, Star & Hirsch, 2009), thus increased activity in this region 
suggests exaggerated threat response. Furthermore, differences in resting state 
functional connectivity between amygdala and higher cortical structures were found 
between SAD and HCs (Pannekoek et al., 2013), suggesting altered emotional 
processing in SAD. 
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Higher brain centres, as well as those at the interface between the prefrontal cortex 
and the deeper emotional centres have also been implicated in the disorder. The 
prefrontal cortex has been implicated in high level cognitive functioning, including 
social cognition and executive control (Bzdok, Laird, Zilles, Fox & Eickhoff. 2013). 
Altered emotional and self-referential processing is implicated by  alterations in 
activation of dorsomedial prefrontal cortical (DMPFC) areas (Amir et al., 2005; 
Blair et al., 2011; Freitas-Ferrari et al., 2010; Goldin, Manber, Hakimi, Canli & 
Gross, 2009; Lorberbaum et al., 2004; Phan et al., 2006; Stein, Hunter, Rolfe & 
Oakes, 2002; Straube et al., 2005). Increased ACC response has been found in 
controls, which implies that they are able to shift attention more readily (Klumpp, 
Post, Angstadt, Fitzgerald & Phan, 2013).  In the case of SAD individuals, it is 
thought that there is a difficulty disengaging from threat stimuli. Furthermore, it has 
been suggested that there is an increased effort and adjustment required by higher 
centres to control more basal structures, such as the amygdala, when individuals with 
SAD are exposed to potentially threatening social stimuli, as evidenced by 
heightened activation followed by a habituation effect observed in the amygdala, 
OFC and thalamus in SAD patients after exposure to emotional stimuli (Sladky et 
al., 2012).  
 
In addition, it appears that patients with SAD activate regions related to self-
referential processing, visual attention and related memory (Dumas et al., 2013). 
Differences in activation have been found in the fusiform gyrus and inferior temporal 
cortex (Etkin & Wager, 2007; Gentili et al., 2008). Increased insula activation has 
been found in individuals with generalised SAD when perceiving emotional faces 
(Klumpp et al., 2013). Individuals with SAD also tend to have an enhanced visual 
cortical response to emotional faces (McTeague, Shumen, Wieser, Lang & Keil, 
2011). Indeed, the insula is thought to be associated with the experience of emotion, 
particularly anxiety (Paulus & Stein, 2006). The fusiform gyrus, also known as the 
fusiform face area, deals specifically with facial processing (Kanwisher, McDermott 
& Chun, 1997). This may be related to gaze anxiety and avoidance behaviour, which 
is discussed later. 
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The most coherent finding among the brain imaging techniques reflect increased 
activity in limbic and paralimbic regions in SAD. The predominance of evidence 
implicating the amygdala strengthens the notion that it plays a crucial role in the 
pathophysiology of SAD. The observation of alterations in pre-frontal regions and 
the reduced activity observed in striatal and parietal areas show that much remains to 
be investigated within the complexity of SAD 
 
While research points towards functional alterations in both basal and higher centres, 
these findings need to be viewed in the light of a recent review of the neuroscientific 
and electrophysiological studies indicating results obtained vary according to 
neuroscientific methods and experimental tasks (Schulz, Mothes-Lasch & Straube, 
2013). This review concluded that there is a lack of systematic studies with 
consistent methodology in order to produce reliable findings. Thus, it is prudent to 
regard the existing findings with care. Furthermore, neurobiological variation found 
in SAD patients across different studies may also be the result of other variables. 
Furmark et al. (2009), for example, note that over-activity in the amygdala may be 
more related to adrenergic genetic polymorphisms rather than directly to SAD. Thus 
variations in research results may be partly related to methodological differences or 
to biological variation influenced by other factors. 
 
Referring to meta-analyses of existing neuroimaging studies on the topic by is useful 
in distilling a coherent picture of neurobiological differences in SAD patients. Etkin 
& Wager (2007)’s quantitative meta-analysis of eight studies (including fMRI and 
positron emission tomography, or PET) revealed increased activation in the 
amygdala and insula in SAD patients. Both of these structures are thought to be 
involved in negative emotional responses (Phan et al. 2006; Stein, Goldin et al., 
2002; Straube et al., 2004; 2005). Freitas-Ferrari et al.’s (2010) systematic review of 
forty-eight studies (including fMRI, PET, and magnetic resonance spectroscopy, or 
MRS, methods) found increased activity in the limbic area, paralimbic regions, and 
amygdala, as well as possible alterations in frontal regions. Hattingh’s (2011) 
likelihood analysis of eleven studies indicated increased activation for SAD patients 
in the hippocampus, amygdala, insula, dorsal striatum, occipital lobe, and 
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cerebellum. Hattingh et al. (2013) followed up with a likelihood analysis of seven 
fMRI studies determined that there was significantly increased activation in the 
amygdala bilaterally, left medial temporal lobe (including parahippocampus), right 
anterior cingulate, postcentral gyrus and right globus palidus in individuals with 
SAD relative to HCs. Taken together, these analyses indicate that combined research 
findings correspond to neuroanatomical models of fear conditioning and demonstrate 
the importance of the limbic system in SAD. 
 
Functional activation differences may be underpinned by structural brain volume or 
cortical thickness differences. Structural investigations of the neurobiology of SAD 
have demonstrated cortical volume differences associated with the disorder. The 
findings of research in this area have been variable, suggesting that a range of 
neurocircuitry is involved in SAD. For instance, some studies have found no 
volumetric differences in whole brain, thalamus, striatum (Potts, Davidson, Krishnan 
& Doraiswamy, 1994), amygdala or hippocampus (Syal et al., 2012), while other 
studies have found either increases or decreases in various regions. Volume 
decreases in the amygdala (Irle et al, 2010; Hattingh, 2011), hippocampus (Irle et al., 
2010, Liao et al., 2011), orbitofrontal, insular (Hattingh, 2011; Syal et al., 2012), 
parietal, and temporal cortex (Syal et al., 2012; Talati, Pantazatos, Schneier, 
Weissman & Hirsch, 2013), including the fusiform gyrus (Syal et al. 2012) have 
been noted in SAD patients. Decreased hippocoampal volume (Irle et al., 2010; Liao 
et al., 2011), thinning of the postcentral cortex (Syal et al., 2012) and decreases right 
rostral anterior cingulate cortex thickness (Frick et al., 2013) have been found to be 
associated with increased symptom severity.  In contrast, increased cortical thickness 
has been associated with SAD in the fusiform and left parahippocampal gyri and the 
cerebellum (Talati et al., 2013), left inferior temporal cortex (Frick et al., 2013), left 
insula, right temporal pole, right anterior cingulate, left insula, right dorsolateral 
prefrontal and parietal cortical areas (Brühl et al., 2013) and medial prefrontal cortex 
(Liao et al., 2011). These variable findings suggest that while it is likely that there 
are structural anatomical differences associated with SAD, the disorder may involve 
a range of complex neurocircuitry. 
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In addition to grey matter volume differences, white matter tract alterations have 
been found in individuals with SAD. Currently, it is thought that the white matter 
tract of the uncinate fasciculus, that connects temporal and frontal brain regions, was 
found to be reduced bilaterally in SAD patients, suggesting a deficiency in 
connection between higher centres and basal structures, such as the amygdala (Bauer 
et al., 2013). Liao et al. (2011) found right medial prefrontal cortex volume and 
corpus callosum connectivity were increased SAD patients (Liao et al., 2011). They 
concluded that these enhancements imply a compensatory mechanism employed by 
those with the disorder. Relatively few studies have been published in this area, 
however, so evidence is contradictory and limited. 
 
Adding to the developing picture of structural anatomical and functional activation 
differences, there is evidence of differences at the molecular level. Evidence from 
the efficacy of SSRIs suggests the role of neurotransmitters, specifically 
dopaminergic and serotonergic circuits, in the disorder’s pathogenesis (Brunello et 
al., 2000; Stein, Hunter et al., 2002; Stein & Seedat, 2007). Furthermore, evidence 
from both non-human and human primates suggests altered regulation of the 
hypothalamic-pituitary-adrenal (HPA) axis. In non-human primates, elevated cortisol 
levels in response to stress, lead to displays of submissive and avoidant behaviour in 
social situations (Sapolsky, 1990; Kalin, Larson, Shelton, & Davidson, 1998). 
Similarly, in humans, increased cortisol response is associated with increased 
avoidant behaviour, suggesting a hyperactive HPA axis response in SAD (Roelofs et 
al., 2009).  
 
Neurocircuitry of embarrassment and blushing 
Some neurological research has been conducted into the experience of emotions 
underlying blushing, but the neural correlates of the blush response itself are 
relatively unknown. As previously mentioned, blushing occurs in response to the 
self-conscious or moral emotions of embarrassment and shame (Shields et al., 1990) 
 
Various neuroimaging studies on social, self-conscious and moral emotions have 
revealed certain brain areas correlated with their expression. The amygdala, a brain 
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region heavily implicated in the conditioning and expression of basic emotions, has 
been implicated in affective response to one’s own moral transgressions, and the 
experience of social emotions (Moll, de Oliveira-Souza, Eslinger et al., 2002; 
Berthoz, Grèzes, Armony, Passingham, & Dolan, 2006; Britton et al., 2006). Social 
emotions have also been found to trigger activation in the superior temporal gyrus, 
hippocampus and posterior cingulate (Britton et al., 2006), upper midbrain and 
thalamus (Moll, de Oliveira-Souza, Bramati, & Grafman, 2002; Moll, de Oliveira-
Souza, Eslinger et al., 2002). Moral emotions (or prosocial emotions) additionally 
recruited the orbital and medial prefrontal cortex and superior temporal sulcus (Moll, 
de Oliveira-Souza, Eslinger et al., 2002; Moll et al., 2007).   
 
Activation patterns for embarrassment, specifically, include the ventrolateral and 
dorsomedial prefrontal cortex, bilateral hippocampus, right anterior temporal cortex, 
and visual cortex (Takahashi et al., 2004). The ventrolateral and dorsomedial 
prefrontal cortex is increasingly active for social transgressions in the presence of an 
audience, and for all moral transgressions. It has been suggested that these regions 
process aversive social stimuli in order to facilitate a change in behaviour from the 
one prompting the aversive reaction to a more beneficial one (Finger, Marsh, Kamel, 
Mitchell, & Blair, 2006). 
 
Understanding the neural correlates of the emotions that are thought to underlie the 
blush response may go some way to suggest the higher level processing that may be 
involved in the blush response. However, no studies of SAD have determined the 
neural correlates of blushing symptoms in this disorder.   
 
Neurocircuitry of gaze behaviour 
Neuroimaging research has determined that eye contact and gaze cues are associated 
with increased cortical activity in the amygdala (Spezio, Huang, Castelli & Adolphs, 
2007; Dumas et al., 2013), ventral striatum  (Kampe, Frith, Dolan & Frith, 2001) and 
superior temporal sulcus (Nummenmaa & Calder, 2009). Pupil dilatation, which is 
thought to play a role in eye contact interactions, is regulated by autonomic pathways 
(Yoshitomi, Ito & Inomata, 1985). It is influenced by emotional salience and by 
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activity in the anterior cingulate cortex and amygdala (Pissiota et al., 2003; 
Critchley, Tang, Galser, Butterworth & Dolan, 2005). Individuals with amygdala 
damage also show increased gaze avoidance (Adolphs, Tranel, Damasio & Damasio, 
1994; Adolphs et al., 2005), lending further support to the idea that the amygdala 
plays an important role in gaze behaviour. 
 
Research into the functional neurology of gaze behaviour in individuals with SAD 
demonstrates that SAD patients and HCs differ in the activation of fusiform, insula, 
anterior cingulate, prefrontal cortex and amygdala in response to gaze (Schneier et 
al., 2009). Heightened brain activation has been observed in the fusiform gyrus (or 
fusiform face area) of SAD patients relative to HCs (Mueller et al., 2009). This 
increased activation is suggestive of hyper-vigilance in individuals with SAD 
(Mueller et al., 2009), increased activation in the neurological fear neurocircuitry in 
response to eye contact (Schneier et al., 2009) and threatening facial expressions 
(Stein, Goldin et al., 2002). This, together with increased pupil dilatation observed in 
individuals with SAD as a result of subjective perception of eye contact, suggests 
increased autonomic arousal and fear in response to eye contact (Honma, 2013). 
However, only a few studies have looked at these neuroanatomical correlates of gaze 
fear and avoidance in SAD patients. Thus, research into this little explored area 
would enhance the understanding of SAD and may inform management of this 
common disorder. 
 
While a number of studies have explored the functional neurobiology of SAD, there 
is still work to be done in resolving methodological heterogeneity in order to move 
towards a more coherent picture of the underpinnings of the disorder. Even less work 
has been done on the structural neurobiology of the disorder. A smattering of studies 
has demonstrated some grey and white matter volume differences in individuals with 
SAD, but these findings have been somewhat contradictory (Brühl et al., 2013).  
 
Treatment of SAD, blushing and gaze avoidance 
The chronicity and significant functional impairment experienced by individuals 
with SAD indicates the necessity for treatment of the disorder as well as possibly 
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specifically targeting salient symptoms. While a number of treatments are available 
for the treatment of SAD in general, targeted treatment for the specific symptoms of 
blushing and gaze avoidance requires attention. The current treatment available for 
blushing is far from ideal, and research into the treatment of gaze avoidance is still in 
its infancy. Treatment improvement or expansion of treatment options relies, at least 
in part, on an improved understanding of the physiological and neurological bases of 
self-conscious emotions, blushing and gaze avoidance behaviour. Indeed, Cuthbert 
and Insel (2013), posit that current diagnostic classifications may not adequately 
reflect the behavioural and neurobiological components of disorders, which impedes 
true understanding of the aetiology as well as treatment development. Furthermore, 
the development of more effective treatments may contribute to the understanding of 
the neurobiology of these. 
 
Treatment of SAD 
SAD is best managed with a combination of psychological and pharmacological 
therapies (den Boer, 1997; Muller et al., 2005). Pharmacotherapies that have been 
used for SAD include selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), reverse inhibitors 
of monoamine oxidase A (RIMAs), benzodiazepines, and beta blockers (den Boer, 
1997; Muller et al., 2005).  
 
A systematic review on these therapies demonstrated medication to be more 
effective than placebo, with SSRIs demonstrated to be the best for first line therapy 
because of their effectiveness, safety and tolerability and use in the treatment of co-
morbidities (Muller et al., 2005). MAOIs and RIMAs are considered for second line 
therapy, with a worse side-effect profile than SSRIs (Muller et al., 2005; Stein & 
Ipser, 2000). Such treatment was also effective in reducing co-morbid depression. 
Results from the review supported short-term therapy with long-term maintenance in 
those who responded. However, while these therapies may be effective in a broad 
range of SAD patients, research into the effectiveness of medication for specific 
phobias, such as fear of public speaking, is limited. Psychological therapy of the 
disorder usually involves cognitive behaviour therapy (CBT), which consists of 
26 
 
restructuring of maladaptive thinking and exposure to situations that provoke 
anxiety, and can be administered at any stage of the treatment process (Muller et al., 
2005; Stein & Ipser, 2000).  
 
Treatment of blushing 
Treatment options available to patients with a fear of blushing include behaviour 
modification, medication, or surgery (Mulkens, Bögels, de Jong, & Louwers, 2001; 
Drott et al., 2002; Connor, Davidson, Chung, Yang, & Clary, 2006). Table 1 
summarises the literature that exists for the treatment of blushing specifically. While 
some therapies used to treat SAD generally can have effects on blushing, these 
studies have not been included. This summary is included here, because while meta-
analyses exist for neuroimaging research in SAD (Hattingh et al., 2013), and for the 
psychological and pharmacological treatment of SAD in general (Muller et al., 2005; 
Stein & Ipser, 2000), no such current summary exists for the blushing or gaze 
avoidance treatment literature (a single review by Neumayer in 2005 addressed 
blushing treatment was only on surgical options and included indications not limited 
to blushing). 
 
There are several medications that may be used for the treatment of fear of blushing 
(erythrophobia), although the effects are mostly as a by-product of treating the 
primary SAD diagnosis. Given the proposed sympathetic mediation of the blush 
response, beta blockers and anxiolytic drugs, that target symptoms related to the 
sympathetic nervous system, have been used by some patients (Drott et al., 2002). 
However, these therapies are ones that are used for the treatment of SAD and not 
blushing specifically, and the efficacy for blushing remains untested (except in one 
study discussed below). A number of individuals seeking surgical intervention have 
previously tried beta-blockers and anxiolytics with limited success (Drott et al., 
2002).  
 
There is some evidence of efficacy for SSRIs, suggesting the involvement of 
serotonergic systems in the blush response. Sertraline, one such SSRI, has been 
found to reduce fear, avoidance and the physiological symptoms, specifically 
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blushing (13% reduction) and palpitations (10% reduction), in patients with social 
anxiety disorder (Connor et al., 2006; Table 1). While the use of SSRIs may be 
beneficial in mild blushers, the magnitude of this reduction may not be sufficient for 
severe cases and surgery may be necessary. For example, Drott et al. (2002) found 
that a number of their patients had unsuccessfully tried SSRIs. Furthermore, the 
work by Connor et al. (2006) was the first randomised-control trial into the use of 
pharmacotherapy in the treatment of blushing. More research is needed into the 
effects of pharmacological management of blushing, before strong conclusions can 
be drawn. 
 
Some researchers recommend that individuals who suffer from fear of blushing 
should first attempt to treat the underlying cause of blushing, using psychological 
therapies before considering the drastic option of surgery (Bracha & Lenze, 2006). 
One such method, CBT, involves decreasing a patient’s anxiety surrounding the 
blush response (Mulkens et al., 2001). Another method, exposure training, involves 
guiding the patient through situations that produce anxiety in order to diminish their 
problematic responses (Scholing & Emmelkamp, 1993). Task concentration is yet 
another method that attempts to redirect the patient’s attention from the bodily 
symptoms they experience to the social task at hand (Bögels, 2006). There is some 
evidence to suggest that these therapies result in improvement in fear of blushing. 
Relaxation techniques can also be tried, but these have been shown to be less 
effective (Bögels, 2006). However, there are very few studies on the effectiveness of 
these therapies, so their success with treating blushing specifically is still largely 
unconfirmed.  
 
In severe cases, patients obtain no relief from either psychotherapy or medication 
and turn to surgery. This more drastic, yet more effective, treatment is an endoscopic 
thoracic sympathectomy (ETS) or endoscopic thoracic block (EBS) by clipping, a 
surgery that interrupts the facial sympathetic innervation of the upper thoracic chain 
(Drott et al., 2002). The surgery, originally used for hyperhidrosis (excessive 
sweating), was first proposed for facial blushing in 1985 (Wittmoser, 1985). It is 
now indicated for hyperhidrosis, facial blushing, digital ischemia or sympathetic 
dystrophy (Kwong et al., 2005).  For facial blushing, surgery or clipping is bilateral 
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and usually occurs at the level of the second and third thoracic (T2-T3) or third and 
fourth vertebrae (T3-T4). While the pathophysiological mechanism of blushing is 
still poorly understood, this surgery has been found to produce a 63-100% reduction 
in facial blushing among patients (Table 1).  
 
However, side effects of this surgery make it an option reserved only for intractable 
symptoms. Undesirable side effects, most commonly compensatory sweating, have 
been reported with a wide range of variability (between 12.5- 88%) of patients 
(Table 1; Bracha & Lenze, 2006; Chou et al., 2006; Smidvelt & Drott, 2011). These 
side effects may lead to regret of having had the surgery (Cameron, 2003). ESB may 
be more advantageous to this end, because of reversibility and reduced complications 
(Lin et al., 1998; Chou et al., 2006). Also, there is some evidence that performing the 
surgery at the T3-T4 level causes less compensatory sweating than at T2-T3 
(Reisveld, 2006), however the T2 level is most commonly blocked for blushing 
complaints (Neumayer, 2005).  Other surgical risks include the complications 
associated with all surgery (failure of procedure, haemorrhage and anaesthetic 
complications), as well as pleural effusion, pneumothorax (air in the pleural space of 
the lung), haemothorax (blood accumulation in the pleural space), and Horner’s 
syndrome (eye palsy involving drooped eyelid with pupil constriction; Cameron, 
2003; Chou et al., 2006; Kwong et al., 2005). The use of a harmonic scalpel 
(Callejas, 2004) or laser (Black, Taylor, Russel, Ariga & Thomas, 2008) instead of 
diathermy may prevent some of the more severe complications compared to 
traditional techniques, however only a few studies have investigated such alternative 
methods. 
 
Even though surgery has been showing to be highly effective in reducing blushing, 
the side-effects and risks of this elective procedure make it less than an ideal 
solution. Furthermore, some experts propose that surgery is the wrong approach to 
fear of blushing (Dijk & De Jong, 2006; Drummond, 2000). Firstly, the surgical side 
effects may be worse than the original symptoms in some patients (Drummond, 
2000). Secondly, evidence of surgical efficacy is has been largely determined by 
uncontrolled retrospective studies. Thirdly, as previously discussed, there is evidence 
29 
 
to suggest that those who fear blushing may not actually blush more than non-fearful 
individuals, and it is rather the fearful preoccupation with blushing that requires 
treatment (Gerlach et al., 2001; Drummond, 2006). Finally, removal of blushing may 
affect the communication of social and moral emotions (i.e. shame and 
embarrassment), thereby affecting social functioning (de Jong, 1999).  
 
Treatment for gaze avoidance 
There are several treatment options available for blushing (despite being 
suboptimal), but treatment available for gaze avoidance is even more limited. So far, 
there is some evidence for the effects of neuropeptide and neurotransmitter 
imbalances affecting gaze behaviour in SAD patients (Gamer, Zurowski & Buchel, 
2010; Laubuschane et al., 2010; Table 1). Oxytocin is a neuropeptide that plays an 
important role in regulating social behaviour in humans and other animals. 
Administration of oxytocin has been found to attenuate amygdala hyperactivity 
activity and increase gaze behaviour in SAD patients (Gamer et al., 2010; 
Laubuschane et al., 2010). SAD patients treated with the SSRI paroxetine displaced 
decreased fear and avoidance of eye contact after 8-12 weeks (Schneier et al., 2011). 
 
Despite the options currently available, there is no ideal treatment for blushing in 
blushing-fearful individuals, and more efficient pharmacotherapies and 
psychotherapies should be investigated. Furthermore, treatment research for gaze 
avoidance still has far to go. Investigating the underpinnings of self-conscious 
emotions, blushing and gaze avoidance behaviour is an important step towards better 
treatment options for SAD patients with these specific complaints. 
  
 
 
Table 1.  
Summary of blushing and gaze avoidance treatment research 
Reference Treatment 
Type 
Total study 
participants 
Participants 
with 
gaze/blushing 
complaints 
Follow-up 
time (months) 
Level of 
surgical 
intervention 
Treatment success and 
satisfaction
  
Treatment side effects and 
complications
 a
 
Gaze avoidance 
Pharmacological* 
Gamer et al. (2010) Oxytocin 46 0 (all HCs) Immediate - 
Increased likelihood of gaze 
towards eyes, with increase in 
posterior amygdala as determined 
by fMRI 
 
- 
Labuschagne et al. 
(2010) 
Oxytocin 36 18 45 (min) - 
Normalisation of amygdala 
activation as determined by fMRI 
 
- 
Blushing 
Pharmacological* 
Connor et al. 
(2006) 
Sertraline 
(SSRI) 
346 346 3 - 
Efficacy 48%, behavioural: 17% 
reduction in fear, 18% reduction 
in avoidance, physiological: 13% 
reduction in blushing, 10% 
reduction in palpitations, 8% 
reduction in sweating 
- 
Psychological** 
Scholing & 
Emmelkamp, (1993) 
CBT vs. 
exposure 
therapy 
35 
35 (30 for 
analysis, 
85.7%) 
Immediately 
after treatment 
then at 3 
- 
No significant difference between 
treatments 
- 
Bögels (2006) 
Task 
Concentration   vs. 
relaxation 
65 24 
Immediately 
after treatment 
then at 3 and 
12 
- 
Task concentration more effective 
than relaxation 
- 
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Reference Treatment 
Type 
Total study 
participants 
Participants 
with 
gaze/blushing 
complaints 
Follow-up 
time (months) 
Level of 
surgical 
intervention 
Treatment success, satisfaction, 
side effects
a 
Treatment side effects and 
complications 
Surgical*** 
Wittmoser (1985) ETS 70 
70 (43 for 
analysis, 
61.4%) 
24 (max) 
T2 – T3 
+ RC 
Efficacy 95% bilateral, 66% 
unilateral 
No major complications 
Yilmaz et al. (1996) ETS 50 11 66 (max) 
Lower 
T1 –T5 
Efficacy 93.3% 
  
CS 67%, 
Complications: 1 Horner’s 
syndrome, 1 neuralgia, 1 
pneumothorax, 4 winged scapula 
 
Drott et al. (1998) ETS 244 
244 
(219 for 
analysis, 95%) 
8 (mean) 
Lower 
T1 –T3 
Efficacy VAS 8.7 before vs. 2.2 
after (74.7% improvement), 
Satisfied 85%, Partially satisfied 
13%, Dissatisfied 2 
 
%, CS 75%. Complications: 2 
pneumothorax, 1 pulmonary 
embolus 
Rex et al. (1998) ETS 1152 244 8 (mean) T2-T3 
Efficacy 96%, Satisfied 85%, 
Partially satisfied, 13%, 
Dissatisfied 2% 
  
CS 59.8% 
Drott et al. (2002) ETS 1314 
1314 
(831 for 
analysis, 63%) 
29 
Lower 
T1-T3 
Efficacy in 95% of patients, VAS 
8.8 before vs. 2.5 after (71.6% 
improvement), Satisfied 85%, 
Partially satisfied 15% 
 
CS 83% 
Lardinois (2002) ETS 37 18 30 (mean) 
T2 – T5 
+ RC 
Efficacy 89%, Satisfied 95%, 
94.5% QOL improvement 
 
CS 44-67%, Complications: 1 
Cerebral emboli with motor 
aphasia, 1 pneumothorax, 2 
Horner’s Syndrome 
 
Rajesh (2002) ETS 26 3 29 (mean) T2 –T4 Efficacy 65% 
CS 77%; Complications: 2 
Horner’s syndrome, 10 
pneumothorax, 2 haemothorax, 2 
surgical emphysema,1 pleural 
effusion, 2 chest infections 
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Reference Treatment 
Type 
Total study 
participants 
Participants 
with 
gaze/blushing 
complaints 
Follow-up 
time (months) 
Level of 
surgical 
intervention 
Treatment success, satisfaction, 
side effects
a 
Treatment side effects and 
complications 
Fishel et al. (2003) 
ETS 
(harmonic 
scalpel) 
486 5 42 (max) T2 –T3 Efficacy 90% 
 
CS 19%, no complications 
 
Neumayer et al., 
(2003) 
ESB 184 18 5 (median) T2 
Efficacy 100% , Satisfied 93.7%, 
Partially satisfied 6.3% 
CS 12.5%, Complications: 1 
pneumothorax, 1 partial 
Horner’s syndrome 
 
Callejas et al. 
(2004) 
ETS 
(diathermy, 
harmonic 
scalpel) 
100 100 20 (max) 
Lower 
T1-T3  
No complications in harmonic 
scalpel group vs. Complications 
in diathermy: 1 temporary 
Horner’s syndrome, 3 persistent 
pain, 9 asymptomatic 
pneumothorax 
Licht et al. (2004) 
ETS 
(diathermy, 
harmonic 
scalpel) 
158 49 26 (median) T2 
Efficacy 43%, Satisfied 25%, 
Some effect 17%, No effect 15%  
CS 81%, Complications: 4 
Horner’s syndrome, 40 
pneumothorax (10 
symptomatic), 1 pleural 
empyema 
 
Adair et al. (2005) ETS 80 59 20 T2 – T3 
Efficacy Score 78 before vs. 26 
after (66.6% score reduction), 
Complete resolution 29%, QOL 
improvement 63% 
  
CS 91%, Complications: 5 
pneumothorax, 2 transient 
Horner’s syndrome, 52 transient 
chest pain 
Neumayer et al. 
(2005) 
ESB 57 27 20.4 (mean) T2 
Efficacy 96.2%, Satisfied 76.9%, 
Partially satisfied 11.5%, Partially 
dissatisfied 11.5% Marked 
improvement 3.8% 
CS 23.1%, Complications: 1 
pneumothorax, 1 partial miosis, 
3 neuralgia 
Kwong et al. (2005) ETS 202 21 13 (mean) T2 Efficacy 90% 
CS 40%, Complications: 1 
pneumothroax, 1 pleural 
effusion, 2 Horner’s Syndrome, 
2 chylothorax 
33 
 
Reference Treatment 
Type 
Total study 
participants 
Participants 
with 
gaze/blushing 
complaints 
Follow-up 
time (months) 
Level of 
surgical 
intervention 
Treatment success, satisfaction, 
side effects
a 
Treatment side effects and 
complications 
Chou et al. (2006) ESB 73 14 
28 ± 10.5 
(mean) 
T2 Efficacy 100% CS 7.1% 
Licht et al. (2006) ETS 180 
180 
(173 for 
analysis, 96%) 
20 (median) 
T2 and 
T2 – T3 
Efficacy 90%, Excellent 55%, 
satisfied 19%, Some effect 16%, 
No effect 10%  
CS 88%, Complications: 1 
pneumothorax, 1 temporary 
Horner’s syndrome 
 
Black et al. (2008) ETS with laser 233 
8 
(6 for analysis, 
75%) 
6-120 (range) T2 – T3 
Efficacy 83%, Satisfied 66.7%, 
Partially satisfied 16.7% No 
improvement 16.7%  
CS 55%, Complications: 1 
pulmonary oedema, 2 bleeding, 
2 failed procedures 
 
Jeganathan et al. 
(2008) 
ETS 163 24 51 (mean) T2 
Efficacy 84%, Failure 16%, 
Recurrence 4.7% 
CS 77%, Complications: 6 
pneumothorax, 1 chronic wound 
 
Fibla et al. (2009) ESB 61 16 
1 week, then 3 
and 12 
T2 Efficacy 95% 
CS 62.2%, Complications: 5 
pneumothorax (4 asymptomatic) 
 
Franco et al. (2011) ETS and PRS 58 18 12-14 
T2 and C7 – 
T1 
Efficacy 72.5% ETS vs. 15% 
PRS, higher QOL improvement 
for ETS 
 
CS 40% 
Smidvelt & Drott 
(2011) 
ETS 3015 536 14.6 T2 – T3 
Efficacy 72.8%, Satisfaction 
73.5% 
 
CS 80% 
Key: CBT= cognitive behavioural therapy, ETS = endoscopic thoracic sympathectomy, ESB = endoscopic thoracic block, PRS = percutaneous 
radiofrequency sympathicolysis, T1 = thoracic vertebra 1, T2= thoracic vertebra 2, T3= thoracic vertebra 3, T4= thoracic vertebra 4, RC = Rami 
communicantes, CS = compensatory sweating, QOL = quality of life, *Randomised control trial, **Treatment outcome trial, ***Uncontrolled, retrospective 
analysis, acomplications reported for total sample 
 
 
 
Summary  
SAD is one of the major psychiatric disorders, thought to account for a third of 
diagnoses. It is characterized by a marked fear of social interaction or scrutiny by 
others. An individual with the disorder may present with a constellation of 
physiological and psychological symptoms, of which blushing and gaze avoidance 
have been demonstrated to be strongly associated (Edelmann, 1990; Gerlach et al., 
2001; Baker & Edelmann, 2002; Bögels, 2006; Bögels & Stein, 2009; Bögels, 2011; 
APA, 2013). The disorder is chronic and severely debilitating in nature and may 
often occur with other co-morbid conditions, such as mood disorders, other anxiety 
disorders and substance abuse.  
 
Given its severity and chronicity, treatment is imperative. First line treatment of SAD 
involves SSRIs, with other options including TCAs, MAOIs, RIMAs, 
benzodiazapines and beta blockers, together with cognitive behavioural therapy. 
Treatment for blushing may comprise CBT and other forms of psychotherapy, as 
well as the medications used in SAD treatment. However, these treatments have 
limited success on the blush response, and surgery may be required to produce 
lasting results. There is some evidence for the use of oxytocin and SSRIs in the 
management of gaze avoidance. However, treatment for these specific components 
of SAD are far from ideal, given the side-effects of surgery and limited exploration 
of gaze avoidance treatment options. This may, in part, be related to our limited 
understanding of the neurobiology of these specific symptoms. 
 
Neurobiological and treatment research has suggested abnormalities in 
neurotransmitters, as well as functional and structural differences in the deep, 
emotional centres and higher centres of the brain. Meta-analysis of the available 
imaging literature indicates increased activation has been demonstrated in the 
amygdala bilaterally, left medial temporal lobe (including parahippocampus), right 
anterior cingulate, postcentral gyrus and right globus palidus in individuals with 
SAD. There is also some evidence for cortical volume and white matter tract 
differences in SAD patients, implicating a range of neurocircuitry that may be altered 
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in the disorder. Dopaminergic, serotonergic circuits and the HPA-axis have also been 
implicated in the pathology of SAD. 
 
Gaze fear and avoidance, and blushing are both potentially adaptive traits that have 
become maladaptive, salient features of SAD. In their adaptive role, both eye contact 
and blushing facilitate non-verbal communication, by conveying important emotional 
information, indicating submissive behaviour or recognition of social transgressions. 
However, in SAD, these behaviours are disordered to the extent of inhibiting 
successful social interactions.  
 
While the neurobiology of SAD is partially understood, investigation into the 
neurobiology of the cardinal symptoms of blushing and gaze avoidance is limited. 
Individuals with SAD have been shown to have altered brain activation in response 
to gaze and avoidance behaviour in the areas of the fusiform gyrus, insula, anterior 
cingulate, amygdala and prefrontal cortex. However, little is known about the 
structural differences underlying gaze fear and avoidance in SAD. While the pre-
frontal cortex, amygdala, temporal, hippocampal, and cingulate regions have been 
implicated in the processing of self-conscious emotions, including embarrassment, 
virtually no research has been conducted into the neurological correlates of blushing. 
Furthermore, while some research has been conducted into how general SAD 
symptom severity relates to structural brain differences, how the severity of these 
specific, salient, SAD symptoms correlate with the altered neurocircuitry observed in 
SAD, remains unexplored.  
 
Furthering an understanding of this has implications for the understanding of SAD 
neurobiology as a whole and also may influence future treatment of the disorder. 
Investigations into the structural brain differences associated with these behaviours 
may shed light into the structural biology of SAD and associated symptoms, further 
developing the picture of the disorder on a structural neurological level. Having 
reviewed the literature, I will now propose a study that aims to address some of these 
questions. 
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AIMS AND OBJECTIVES 
In light of the areas requiring further investigation, the aim of this research project 
was to study the neuroanatomy of blushing propensity and gaze avoidance in 
participants with SAD. The objectives of this were to: 
1. Determine whether differences exist between participants with SAD and controls on 
measures of blushing and gaze anxiety and avoidance. 
2. Determine whether these differences correlate with brain volume differences in 
participants with SAD versus controls.  
 
I hypothesised that SAD patients and HCs would differ significantly on measures of 
blushing and gaze behaviour, given my argument that these are cardinal symptoms of 
SAD. Furthermore, I hypothesised that these symptoms would be associated with 
structural brain volume differences associated with these symptoms. Based on the 
literature of blushing and gaze neurocircuitry, I thought it plausible that these 
differences may be in regions associated basic, social and moral emotions, autonomic 
pathways and the amygdala. 
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METHODS 
 
Participants 
Participants were recruited as patients of local psychiatrists and psychologists, 
community-based advocacy groups via advertisements placed in newspapers and 
from university campuses. Only participants who were over the age of 18 and were 
right handed were initially considered. Those who did not give consent, had co-
morbid psychiatric or neurological illnesses, were psychotic or unable to adequately 
comprehend the procedure were excluded. Approximately two-thirds of all 
participants who were recruited were excluded as a result of co-morbid diagnoses or 
other exclusion criteria. The remainder were included in the study.   
 
Participants in the SAD group (n = 18) consisted of ten SAD males and eight SAD 
females, while there were seven males and eleven females in the HC group (n = 18) 
respectively.  SAD patients and HCs were similar in age and education level with no 
significant differences between them (Table 2). All participants were assessed by a 
clinical psychologist, who conducted a diagnostic interview with each. Participants 
included in the SAD group had a primary diagnosis of generalized social anxiety 
disorder without co-morbid psychiatric diagnoses on Axis I of the DSM-IV (The 
DSM-V had not yet been released at the time of data collection). The Structured 
Clinical Interview for DSM-IV was used to determine the presence of co-morbidities 
(First, Spitzer, Gibbon & Williams, 2012). None of the HCs had psychiatric or 
neurological diagnoses. All participants were right handed. Ten SAD patients and six 
HCs responded to follow up questionnaires. Data from these participants will be used 
in the current study. None of the SAD participants or healthy controls (HCs) were on 
any psychotropic medications when scanned or when they completed the 
questionnaires. 
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Table 2 
Descriptive statistics (mean, standard deviation and effect size) and independent sample t-
tests for SAD patients and HCs for age and education level (n = 18) 
 SAD 
Mean (SD) 
HC 
Mean (SD) 
SAD 
Range 
HC 
Range 
t p df 
Age 30.5(9.1) 30.7(8.1) 19 – 52 19 - 44 0.06 0.954 21 
Education level 7.12 (0.89)* 6.8 (0.92) 6 – 8 6 – 8 -0.89 0.385 19 
Key: HC=Healthy Controls, SAD=Social Anxiety Disorder patients, CSF=Cerebrospinal 
Fluid, SD = standard deviation, Education: 6= grade 11-12, 7= college/technicon, 8= 
University *Missing data: n=10 for education in SAD group 
 
Materials 
Structural MRI 
An MRI scanner was used to structurally image the brains of participants. 
Neuroimaging was performed on a 3T Allegra MRI scanner (Siemens Medical 
Systems/MAGNETOM, Erlangen, Germany) at Cape Universities Brain Imaging 
Centre. Images were acquired using the following parameters: spatial resolution 0 
1.0×1.0×1.0 mm3; slices 0 160; matrix 0 179×256; TR 0 2,300 ms; TE 0 3.93 ms; TI 
0 1,100 ms and flip angle of 12°. The images were whole brain T1-weighted 3D 
magnetization-prepared rapid gradient echo (MPRAGE) (Brookeman, 1990). 
 
Administered Scales 
The scales administered were the Liebowitz Social Anxiety Scale (LSAS; Appendix 
A), the Blushing Propensity Scale (BPS; Appendix B), and the Gaze Anxiety Rating 
Scale (GARS; Appendix C). Detail on the scales, including content, scoring and 
reliability are outlined here. 
 
The Liebowitz Social Anxiety Scale (LSAS; Leibowitz, 1987) was administered to 
all participants in order to determine the severity of social anxiety in individuals 
across the SAD and HC groups, as done by Heimberg et al. (2000). The LSAS 
consists of 48-items, each describing a situation that is potentially anxiety inducing 
across a range of social and performance situations (Leibowitz, 1987). Participants 
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rate how fearful or anxious the situation would make them feel on a 4 point scale 
from “none” to “severe” (24 items) and how often they would avoid the situation on 
a 4 point scale from “never” to “usually” (24 items). A score less than 50 indicates a 
clinically insignificant level of social anxiety, between 55-65 indicates a moderate 
level, between 65-80 indicates a marked level, between 80-95 indicates a severe 
level, and above 95 indicates a very severe level. This measure has been found to 
have good internal consistency (Cronbach’s α = 0.95) and test-retest reliability in 
North American samples (r = 0.83; Baker, Heinrichs, Kim & Hoffman, 2002).  
 
The Blushing Propensity Scale (BPS; Leary & Meadows, 1991) was used to 
determine the degree to which participants blush in everyday social situations. The 
BPS consists of 14 items, each describing a social situation. Participants indicate 
how often they would feel themselves blush in each situation on a 5-point scale from 
‘never’ to ‘always’. This scale has high internal consistency (Cronbach’s α = 0.92) 
and a high test-retest reliability in North American samples (r = 0.93; Mulkens et al., 
1999). The BPS has been used in a number of previous blushing studies (de Jong & 
Peters, 2005; Drummond et al., 2007; Mulkens et al., 1999). From an unpublished 
pilot study (van der Merwe, 2008), high scores on the BPS were found to be 
correlated with a greater embarrassment and blush response. 
 
The Gaze Anxiety Rating Scale (GARS; Schneier et al., 2011) was used to measure 
the degree of anxiety and avoidance participants experienced in response to eye 
contact made across a variety of social situations. Questions consist of 17 items that 
describe a variety of social situations including speaking to someone perceived to be 
attractive, being complemented and delivering a speech. Participants were required 
to rate their level of fear and avoidance to making eye contact in each of the 
situations within the past week. Similar to the LSAS, there are two scales to each 
item. Scores for each item for fear and avoidance of eye contact range from 0 (no 
anxiety/no avoidance) to 3 (a lot of anxiety/avoid a lot). The total score is determined 
by adding all the items. Avoidance and anxiety subscales are highly correlated 
(r=0.90, p<0.01; Langer, Rodebaugh, Menatti, Weeks & Schneier, 2013). The GARS 
has been found to be a psychometrically valid scale for measuring gaze anxiety and 
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avoidance consistency (Langer et al., 2013); it is significantly associated with social 
anxiety severity in both non-patient and social anxiety disorder patients, and has 
demonstrated good internal consistency (Cronbach’s α = 0.96 for SAD patients and α 
= 0.95 for non-patients) and test-retest reliability in North American samples (r = 
0.99, p< 0.001; Schneier et al., 2011). 
 
Procedure 
Individuals interested in participating in the study were first screened for exclusion 
criteria. Those who were eligible for inclusion were invited to attend an MRI 
scanning session at CUBIC. Participants underwent structural, resting state scans on 
the 3T Allegra scanner (acquisition details below under “materials”). Participants 
were then invited to complete additional scales after they had completed their scans. 
Both SAD and HCs were administered the LSAS, BPS and the GARS 
questionnaires. Thirteen SAD patients and eight HCs returned completed 
questionnaires. Of these, most completed all questionnaires, while two HCs 
completed only the LSAS. Multiple attempts to obtain the missing data were made, 
including email and telephone calls. However, it remained impossible to contact 
some participants.   
 
This study was conducted in accordance with the guidelines of The Declaration of 
Helsinki (Brazil, 2013) and the Medical Research Council of South Africa’s 
guidelines (2008) on the ethical conduct of research studies in humans. The study 
protocol received approval from the Human Research Ethics Committee of 
University of Cape Town. Participation in this study was voluntary and participants 
gave written informed consent prior to taking part in the study. All participants were 
told that all data collected were kept strictly confidential and that the results of the 
study would be shared without compromising confidentiality.  It was made clear to 
all participants that they were free to refuse to participate, or to withdraw from the 
study at any point. 
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MRI Data analysis 
After manually reorienting and realigning the cross-hair on the AC-PC plane in all of 
the nifty converted DICOM T1 images, and initial quality control for signal artefacts, 
morphological changes were calculated in grey matter by segmenting from white 
matter and cerebrospinal fluid using the voxel-based morphometry (VBM) unified 
segmentation approach (Ashburner & Friston, 2005) in Statistical Parametric 
Mapping (SPM8) (www.fil.ucl.acuk/spm8). Following this segmentation procedure, 
probability maps of grey matter were "modulated" to account for the effect of spatial 
normalisation, by multiplying the probability value of each voxel by its relative 
volume in native space before and after warping. Grey matter images based on 
probability maps at each voxel were spatially normalised to the Montreal 
Neurological Institute (MNI) template and then co-registered using the same 
segmented template. Modulated images were smoothed with an 8 mm 'Full Width 
Half Maximum [FWHM]' Gaussian kernel, consistent with other recent VBM studies 
REFS. This smoothing kernel was applied prior to statistical analysis, to reduce 
signal noise and to correct for image misregistration. 
 
Statistical analysis of MRI and questionnaire data 
The data was tested for normality, and t-tests were run to compare the means of the 
SAD and HC groups for test scores, demographic variables and brain volumes. The 
full sample (n = 18) was used for brain volume t-test analyses, while smaller sample 
sizes were used for analyses with scale results and demographic variables, because of 
missing data. Correlations between the LSAS, BPS and GARS were calculated to 
determine the strength of association between measures. Effect sizes were calculated 
using Cohen’s d (Thalheimer & Cook, 2002). Post-hoc analyses were used to 
determine the statistical power of those results with large t-values but were not 
statistically significant, in order to determine the required sample size to yield 
significant results.   
 
A contrast analysis in VBM, between SAD and HC was conducted, using age, 
education level and total matter volume as covariates of no interest.  Sex variables 
were not used because of the small sample size. While these demographic variables 
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are by no means exhaustive, it was reasoned that these variables are most associated 
with differences in global brain volume in any given population, and the commonly 
used covariates used in VBM analyses. Thus, we controlled for these factors in an 
attempt to isolate the effects of blushing and gaze data on brain volume differences. 
Further, the LSAS was added as a regressor of interest to examine how anxiety 
influences the differences in brain volume in the total cohort.   
 
In regression models, we firstly examined the relationship between brain volume 
data and LSAS scores, with age, education and total brain volumes as covariates of 
no interest.  This was to determine how anxiety is associated with brain volume in 
the total cohort. Secondly, we examined BPS and GARS in separate regression 
models to determine the effects of these sub-scores on brain volume in the total 
sample.  In a final model, we examined BPS and GARS together to determine 
whether they have a different impact on brain volume in the total cohort. Within 
group analyses could not be done due to the small sample sizes. The results obtained 
from the regression analyses were corrected using familywise error (FWE). 
However, uncorrected results as well as uncorrected results are reported here, given 
the exploratory and preliminary nature of this research. 
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RESULTS  
 
Test of normality 
Normality testing on the data of HCs and SAD patients indicated that most of the 
data was normally distributed except for the demographic variables of age (AD2= 
p=0.011), education (AD2 = 2.29, p<0.001), and CSF volume (AD2 = 1.47, p<0.001).  
 
Administered Scale Scores  
There were significant differences between SAD patient and HC scores on the LSAS, 
BPS and GARS scales. SAD patients scored significantly higher on all measures than 
HCs (Table 3). The effect sizes of these differences were also large (all differences 
approximately equal to or greater than two standard deviations). There was a 
significantly strong positive correlation between LSAS scores, blushing propensity 
scores and gaze total scores across patients (p<0.001; Figures 1-3).  
 
Scores on the LSAS ranged from 51 – 133 for SAD participants and 4 – 25 for HCs 
(out of a theoretical maximum of 144). All of the SAD patients scored in the 
significant range for social anxiety (significant score >50), with three participants 
scoring just above the lower bound of significance (score of 50-55), two had marked 
social anxiety (score of 65-80), three had a severe level (score of 81-95), and six had 
a very severe level (score above 95). None of the HCs had a clinically significant 
score on the LSAS.  
 
BPS Scores ranged from 37 – 70 for SAD participants and 18-45 for HCs (out of a 
theoretical maximum of 70). GARS total scores ranged from 10-91 (out of a 
maximum of 102) for SAD participants and 0-16 for HCs. GARS anxiety subscale 
scores ranged from 8-46 for SAD participants and 0-13 for HC (out of a maximum of 
51), while GARS avoidance subscale scores ranged from 1-45 for SAD participants 
and 0-4 for HCs (out of a maximum of 51).  
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Table 3 
Descriptive statistics (mean, standard deviation and effect size) and independent 
sample t-tests of SAD patients and health controls for scores on anxiety, blushing 
and gaze scales (SAD n=16, HC=10) 
Scale Scores SAD 
Mean (SD) 
HC 
Mean (SD) 
t P df Effect size 
(Cohen’s d) 
Liebowitz Score (Total) 89(24.8)* 12(7.5)* -11.07 <0.001 18.11 3.88 
Blushing Score (Total) 53(9.4)* 27(10)* -5.41 <0.001 9.20 2.90 
Gaze (Anxiety) 27(11.8)* 6(4.9)* -5.82 <0.001 18.87 2.13 
Gaze (Avoid) 24(13.5)* 2(4.9)* -6.13 <0.001 15.10 1.97 
Gaze (Total) 51(24.6)* 8(6.4)* -6.26 <0.001 17.69 2.11 
Note: HC = Healthy Controls, SAD = Social Anxiety Disorder patients, SD = 
standard deviation, *Missing data = HC: Liebowitz score total n = 8, Blushing score 
total n = 6, gaze anxiety, avoidance and total n = 6, SAD: Liebowitz score total n = 
15, Blushing score total n = 15, Blushing score total n = 13).  
 
 
 
Figure 1. Correlation between social anxiety and blushing propensity (r=0.798) 
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Figure 2. Correlation between social anxiety and gaze total score (r=0.893) 
 
 
 
 
Figure 3. Correlation between blushing propensity and gaze total score (r=0.789) 
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Structural grey matter differences between participants with Social Anxiety 
Disorder and healthy controls 
T-tests did not yield any significant differences in the mean volumes of any brain 
regions between SAD patients and HCs for the total sample (Table 4). However, 
several brain regions had medium to medium to large effect sizes and high t-
statistics, suggesting that differences in some brain volumes between SAD and HCs 
may be of interest. SAD patients had less grey matter volume than HCs (46ml mean 
difference with strong effect; Table 4). Less volume was also found for SAD patients 
in both left and right anterior cingulate cortex (ACC) volume (0.5ml and 0.4ml mean 
difference for left and right ACC respectively, with medium effect; Table 4). 
Similarly, SAD patients had less left and right dorsolateral prefrontal cortex 
(DPLFC) volume than HCs (0.6ml and 1.0ml mean difference for left and right 
DLPFC respectively, with medium effect; Table 4). While analysis of brain volumes 
was conducted on the full sample of 18 SAD and 18 HCs, an alternative analysis 
using the sample that was subsequently used for the other analyses is included in 
Appendix D. The difference between the two analyses was negligible so the results 
from the large analysis are reported here. 
 
Post-hoc analysis (Table 5) for brain volume differences indicates that, given the 
sample sizes, the statistical power of correctly explaining differences for the 
medium-sized effects (total grey matter volume, left and right ACC, and left and 
right DLPFC), the probability of correctly indentifying the difference between the 
SAD and HC cases is between 19-39%. The minimum sample size required to 
explain the medium-sized effects to a 95% certainty is 79 for total grey mater 
volume, 87 and 100 for left and right ACC respectively, and 82 and 86 for left and 
right DLPFC respectively. 
  
 
 
Table 4  
Descriptive statistics (mean, standard deviation and effect size) and independent sample t-tests of SAD 
patients and health controls for brain volumes (n=18) 
Scale Scores 
SAD 
Mean (SD) 
HC  
Mean (SD) 
t p df 
Effect size 
(Cohen’s d) 
Total brain volumes       
Grey Matter (ml) 703(64) 742(69) 1.73 0.093 34 0.59 
White Matter (ml) 474(57) 482(54) 0.43 0.669 34 0.15 
CSF (ml) 1177(112) 1223(118) 1.21 0.234 34 0.42 
Total Intracranial volume (ml) 1700(284) 1801(222) 1.19 0.245 32 0.41 
    Grey matter volumes 
Left Insula (ml) 7.4(0.7) 7.6(1.0) 0.54 0.592 32 0.19 
Right Insula (ml) 7.0(0.6) 7.0(0.9) 0.35 0.730 31 0.12 
Left ACC (ml) 6.1(0.7) 6.5(0.8) 1.65 0.108 33 0.57 
Right ACC (ml) 5.2(0.7) 5.5(0.7) 1.54 0.133 34 0.53 
Left Hippocampus (ml) 3.9(0.4) 3.9(0.4) 0.23 0.820 33 0.08 
Right Hippocampus (ml) 3.7(0.4) 3.7(0.5) 0.05 0.960 33 0.02 
Left Amygdala (ml) 1.0(0.1) 1.1(0.1) 0.47 0.644 32 0.16 
Right Amygdala (ml) 1.0(0.1) 1.1(0.1) 0.69 0.497 32 0.24 
Left DLPFC (ml) 11.3(1.3) 12.2(1.6) 1.70 0.098 33 0.58 
Right DLPFC (ml) 13.1(1.6) 14.1(2.0) 1.66 0.107 32 0.57 
Note: HC = Healthy Controls, SAD = Social Anxiety Disorder patients, CSF = Cerebrospinal 
Fluid, SD = standard deviation, ml = millilitres, ACC = anterior cingulate cortex, DLPFC = 
dorsolateral prefrontal cortex.  
 
 
Table 5  
Post-hoc power calculations for brain volume differences between SAD and HC participants 
(n = 18) 
 
Post-Hoc Power Calculations 
 
 
Statistical Power* Required sample size** 
 
Total brain volumes 
 
 
Grey Matter (ml) 0.39 79.39 
White Matter (ml) 0.07 1257.98 
CSF (ml) 0.13 346.27 
Total Intracranial volume (ml) 0.21 167.53 
Grey matter volumes 
 
Left Insula (ml) 0.08 797.86 
Right Insula (ml) 0.06 1930.53 
Left ACC (ml) 0.36 86.73 
Right ACC (ml) 0.32 99.54 
Left Hippocampus (ml) 0.06 4452.61 
Right Hippocampus (ml) 0.05 92443.09 
Left Amygdala (ml) 0.07 1075.85 
Right Amygdala (ml) 0.10 497.62 
Left DLPFC (ml) 0.38 81.60 
Right DLPFC (ml) 0.36 86.02 
Note: Values in bold indicate those that had medium Cohen’s d effect sizes, *Probability of 
observing Cohen's d given samples size and significance, **Number of samples required for 
95% statistical power to give observed Cohen's d 
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Regression analysis taking the variables of age, education and total matter volume as 
covariates of no interest, revealed a greater grey matter volume in HCs in the regions 
of left occipital cortex, left anterior cingulate and right inferior parietal lobe when 
compared to SAD patients (Table 6; Figures 4-10). In this model, SAD patients did 
not have any areas that were larger than HCs. However, when LSAS score was taken 
as the predictor. SAD patients had significantly higher volumes in the left premotor 
cortex (Brodmann area 8), right hippocampus and left orbitofrontal cortex 
(Brodmann area 47). Accounting for LSAS score demonstrated a significantly larger 
volume in right superior temporal cortex (Brodmann area 42), while diminishing the 
significance of the differences that were found in the first model that only accounted 
for covariates of age, education and total matter volume.  
 
  
 
 
Table 6 
Contrast between SAD patients and healthy controls (HCs) covarying or age, education and total matter volume, with LSAS score as a regressor of interest 
Brain regions MNI Coordinates Cluster size (voxels) z p 
 X Y Z    
SAD > HC 
----- --- --- --- ---  --- 
HC > SAD 
Left occipital cortex (Brodmann area 18) -40 -60 -20 63 4.43 <0.01 
Left Anterior Cingulate -2 26 2 37 5.26 <0.01 
Right inferior parietal lobe (Brodmann area 7) 40 -20 32 32 3.79 <0.01 
SAD > HC (with LSAS score as regressor) 
Left premotor cortex (Brodmann area 8) -32 16 44 69 4.49 <0.01 
Right hippocampus 32 -22 -10 38 3.59 <0.01 
Left orbitofrontal cortex (Brodmann area 47) -20 16 -30 32 3.44 <0.01 
HC >SAD (with LSAS score as regressor) 
Right superior temporal cortex (Brodmann area 42) 60 -34 18 25 3.93 <0.01 
 
 
 
 
Figure 4. Contrast analysis between SAD patients and HCs showing greater volume in left 
occipital cortex for HCs, p < 0.01, uncorrected peak value, Note: colour bar = F-score 
 
 
 
Figure 5. Contrast analysis between SAD patients and HCs showing greater volume in left 
anterior cingulate (ACC) for HCs, p < 0.01, uncorrected peak value, Note: colour bar = F-score 
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Figure 6. Contrast analysis between SAD patients and HCs showing greater volume in right 
inferior parietal lobe for HCs, p < 0.01, uncorrected peak value, Note: colour bar = F-score 
 
 
Figure 7. Contrast analysis between SAD patients and HCs accounting for LSAS score, 
showing greater volume in left premotor cortex for SAD, p < 0.01, uncorrected peak value, 
Note: colour bar = F-score 
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Figure 8. Contrast analysis between SAD patients and HCs accounting for LSAS score, 
showing greater volume in right hippocampus for SAD, p < 0.01, uncorrected peak value, Note: 
colour bar = F-score 
 
 
Figure 9. Contrast analysis between SAD patients and HCs accounting for LSAS score, 
showing greater volume in left orbitorfrontal cortex (OFC) for SAD, p < 0.01, uncorrected peak 
value, Note: colour bar = F-score 
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Figure 10. Contrast analysis between SAD patients and HCs accounting for LSAS score, 
showing greater volume in right superior temporal cortex for HC, p < 0.01, uncorrected peak 
value, Note: colour bar = F-score 
 
 
For regression with age, education and total matter volume as covariates of no 
interest, the brainstem volumes in SAD patients were increased for higher blushing 
scores, while the volumes of left inferior parietal lobe (Brodmann area 7) and left 
occipital cortex (Brodmann area 18) were decreased for higher blushing scores 
(Table 5; Figures 11-13). The volume of left inferior parietal lobe was significant at 
the cluster level. 
 
Again, running the regression with age, education level and total matter volume as 
covariates of no interest, with total gaze fear and avoidance score as the variable of 
interest, it was found that no brain regions were increased in SAD patients. However, 
there were decreases in matter volume of SAD patients when compared to HCs as 
gaze scores increased for right posterior cingulate cortex (Brodmann area 31) and 
right occipital lobe (Brodmann area 19) and right fusiform gyrus (Brodmann area 20) 
(Table 7; Figures 14-16). The right occipital lobe size decrease was significant at the 
cluster level. 
 
Using both blushing scores and total gaze fear and avoidance scores as variables of 
interest (once again controlling for age, education level and total matter volume), it 
was found that as blushing and gaze scores increased, the brainstem volume was, 
again, significantly larger (Table 7; Figure 17). In contrast, the pons/cerebellum 
(significant at the cluster uncorrected level), left inferior parietal lobe, right 
cerebellum (significant at the cluster uncorrected level) and left cerebellum volumes 
decreased with increased scores in both score measures (Table 7; Figures 18-19). 
Bilaterally increasing cerebellar volume was also observed for an interaction 
between increased blushing severity and decreased gaze symptom severity (cluster 
level FWE corrected value; Table 7; Figure 20). 
 
 
 
Table 7 
Regression analyses in blushing and gaze scores in relation to brain volume in SAD patients (corrected for age, education and total matter volume) 
Brain regions MNI Coordinates Cluster size (voxels) z P 
 X y Z    
Positive regression with Blushing Total score 
     Brainstem 0 -12 -38 31 3.58 <0.01 
Positive regression with Gaze Total score 
     --- --- ---  ---  --- 
Negative regression with Blushing Total score 
     Left inferior parietal lobe (Brodmann area 7) -32 -60 42 43 4.27 0.04* 
     Left occipital cortex (Brodmann area 18) -12 90 12 34 3.53 <0.01 
Negative regression with Gaze Total score 
     Right posterior cingulate cortex (Brodmann area 31) 14 -58 24 35 3.74 <0.01 
     Right occipital lobe (Brodmann area 19) 48 -82 2 61 3.74 0.03* 
     Right fusiform gyrus (Brodmann area 20) 40 -8 -28 31 3.59 <0.01 
Positive regression Blushing + Gaze total 
     Brainstem -2 -12 -38 31 4.01 <0.01 
Negative regression Blushing + Gaze total 
      Pons/cerebellum 2 -44 -60 115 4.01 0.001* 
      Left inferior parietal lobe -30 -62 42 30 3.24 <0.01 
      Right cerebellum 12 -70 -52 66 3.46 0.009* 
      Left cerebellum -14 -90 -26 30 3.22 <0.01 
Interaction (Increased blushing, decreased gaze) 
     Left cerebellum -14 -70 -56 827 4.14 <0.001** 
     Right cerebellum 8 -36 -50 346 3.84 <0.001** 
*Cluster level uncorrected p value, **Cluster level FWE corrected p value 
 
 
 
Figure 11. Positive regression showing increased brainstem volume with increased blushing 
severity, p < 0.01, uncorrected peak value, Note: colour bar = t-score 
 
 
 
Figure 12. Negative regression showing decreased left inferior parietal lobe volume with 
increased blushing severity, p = 0.04, cluster level uncorrected value, Note: colour bar = t-score 
 
58 
 
 
Figure 13. Negative regression showing decreased left occipital cortex volume with increased 
blushing severity, p < 0.01, uncorrected peak level value, Note: colour bar = t-score 
 
 
 
Figure 14. Negative regression showing decreased right posterior cingulate cortex (PCC) 
volume with increased gaze symptom severity, p < 0.01, uncorrected peak level value, Note: 
colour bar = t-score 
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Figure 15. Negative regression showing decreased right occipital lobe volume with increased 
gaze symptom severity, p < 0.03, cluster level uncorrected value, Note: colour bar = t-score 
 
 
 
Figure 16. Negative regression showing decreased right fusiform gyrus volume with increased 
gaze symptom severity, p < 0.01, uncorrected peak level value, Note: colour bar = t-score 
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Figure 17. Positive regression showing increased brainstem volume with increased blushing 
and gaze symptom severity 
 
 
 
Figure 18. Negative regression showing decreased cerebellum volume bilaterally with 
increased blushing and gaze symptom severity: right cerebellum p = 0.009, cluster level 
uncorrected value; left cerebellum p < 0.01, uncorrected peak level value; Pons/cerebellum 
result (not shown), p=0.001, cluster level uncorrected value,  Note: colour bar = t-score  
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Figure 19. Negative regression showing decreased left inferior parietal lobe volume with 
increased blushing and gaze symptom severity, p < 0.01, uncorrected peak level value, Note: 
colour bar = t-score 
 
 
 
Figure 20. Interaction showing increased cerebellar volume bilaterally with increased 
blushing and decreased gaze symptom severity, p < 0.001, cluster level FWE corrected value, 
Note: colour bar = t-score 
 
 
DISCUSSION 
The aim of this research was to study the neuroanatomy of the blushing and gaze 
avoidance in patients with SAD. The objectives were firstly to determine if there 
were differences between individuals with SAD and HCs regarding their blushing 
propensity and gaze avoidance behaviour and fear of gaze; and secondly to determine 
whether these differences correlated with structural brain differences in the brains of 
participants with SAD relative to controls. At the same time, looking at the structural 
brain differences between SAD and HCs may support or add to the developing 
picture of research on the topic of SAD neurobiology. I will now discuss the findings 
pertaining to these objectives in light of the current understanding and research in the 
field. 
 
Objective 1: Blushing propensity and gaze fear and avoidance symptoms in SAD 
Significant differences were found between the SAD and HC groups for all symptom 
scales (including the LSAS, BPS and Gaze). Importantly, this indicates that the SAD 
group had significantly increased levels of social anxiety symptoms (as measured by 
the LSAS) when compared to the HCs. This corroborates the clinical diagnosis that 
determined the grouping of participants into patient and control groups. Thus, the 
SAD group had symptoms representative of their psychiatric diagnosis, as determined 
by valid and reliable measures (Leary & Meadows, 1991; Leibowitz, 1987; Schneier 
et al., 2011). This indicates that the SAD group and HCs were clinically distinct from 
each other, and thus a comparison of differences related to these clinical symptoms 
could be justified. 
 
The scores on various scales used to determine symptom severity, specifically 
including the symptoms of interest (blushing and gaze fear and avoidance), correlated 
strongly with each other. This suggests that both blushing and gaze fear and 
avoidance symptoms tend to co-occur, and that increasing prominence of both 
symptoms in an individual correlates with symptom severity of SAD, as measured by 
the LSAS. Furthermore, significant differences were found between SAD patients 
and HCs for both blushing propensity and gaze fear and avoidance (as measured by 
the BPS and Gaze respectively). These findings are congruent with the current 
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understanding that both blushing (Bögels, 2006; Bögels & Stein, 2009; Bögels et al., 
2010; Drott, 2004; Edelmann, 1990; Gerlach et al., 2001) and gaze fear and 
avoidance (Schneier et al., 2011; Weeks et al., 2013) are considered to be cardinal 
symptoms of SAD. Furthermore it suggests that the two symptoms tend to occur 
together as part of the symptomatology of the disorder.  
 
 
However, while these symptoms are thought to be important in SAD, the 
heterogeneity of symptom presentation in this disorder means that the presence of 
these symptoms may be less prominent or absent in some patients. It has been 
proposed that two or three subtypes of SAD exist, with different levels of 
physiological arousability, behavioural and cognitive responses (Öst, Jerremalm & 
Johannson, 1981; Turner & Beidel, 1985). Öst et al (1980) identified physiological, 
cognitive and behavioural responders. Turner & Beidel (1985) determined that while 
SAD patients generally all have highly negative cognition, they may either have low 
or high physiological arousability. Thus, it is important to acknowledge that these 
symptoms may be hallmarks in only a subset of SAD patients. 
 
Despite this heterogeneity in symptom presentation, the findings of the current 
research, together with those of previous research, suggest that these symptoms 
should be given adequate attention when treating individuals with SAD. This is 
because these symptoms may play a large role in both the manifestation of the 
disorder in certain individuals, and in the debilitating effects that the disorder has on 
daily functioning. Fostering a greater understanding of the underpinning 
neurobiology of these symptoms may assist with the optimal treatment options and 
recommendations for these specific complaints as well as for the disorder as a whole. 
This is in line with the idea of Research Domain Criteria (RDoC), in which a more 
comprehensive understanding of psychiatric disorders is developed by investigating 
the genetic, neuroscientific and cognitive components that comprise these (Cuthbert 
& Insel, 2013). In this instance, furthering the understanding of the underpinnings of 
blushing and gaze fear and avoidance symptoms of SAD may assist in this 
endeavour. 
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Objective 2: Structural neurological differences in relation to blushing 
propensity and gaze fear and avoidance  
Structural differences between SAD patients and HCs 
Before undertaking a detailed analysis of how blushing and gaze symptoms correlate 
with structural brain volume differences in the context of SAD, it is necessary to 
explore what the data set contains regarding structural brain volume differences 
between SAD patients and HCs generally. Direct comparison of grey matter volumes 
of SAD patients and HCs to each other (before taking demographic variables into 
account), demonstrated medium to large effect sizes, yet no statistically significant 
differences for the sample size, for total grey matter volume, left and right ACC, left 
and right DLPFC and right amygdala. The medium to high effect sizes of these brain 
region differences suggest that while these results are not statistically significant at 
the 95% confidence level, that they are still of interest. The post-hoc power 
calculations indicate that while the difference between the groups cannot be asserted 
to the desired statistical certainty, there appears to be signal within the noisy data. 
Higher sample sizes would be required for increased certainty regarding these 
differences. However, in light of the magnitude of the effect sizes, it is useful 
consider these brain regions as areas of interest, and these will now be discussed as 
areas of possible difference between HCs and SAD patients. 
 
A medium effect size was observed for volume differences between the total grey 
matter volume of HCs and SAD patients, with SAD patients having less volume. This 
is in line with previous research that has found decreased volumes in various brain 
regions in SAD patients (Hattingh, 2011; Irle et al., 2010; Liao et al., 2011; Syal et 
al., 2012), contributing to overall grey matter decreases. This is in contrast to other 
studies have found increased cortical thickness, with no deceases in SAD patients 
(Brühl et al., 2013; Frick et al., 2013; Talati et al., 2013). Furthermore, fMRI research 
(Etkin & Wager, 2007; Freitas-Ferrari et al., 2010; Hattingh et al., 2013) suggests 
increased activation in SAD patients, which intuitively seems to contradict these 
findings of volume decreases. These inconsistencies will be discussed later in this 
section. 
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Decreased volume in the left and right ACC (with medium effect size) found in this 
analysis is congruent with the findings of Klumpp et al. (2013) and Frick et al. 
(2013), who found increased ACC response in HCs and a correlation of decreases in 
this area with symptom severity respectively. The ACC has been implicated in 
regulatory processes of emotional regulation (Goldin et al., 2009), specifically 
attention, emotional expression and cognitive appraisal (Etkin, Egner & Kalisch, 
2011). Decreased ACC volume suggests that SAD patients may experience altered 
emotional regulation and cognitive processing of social situations. Furthermore, this 
region has been implicated in altered activation in gaze behaviour and the fear 
circuitry of SAD (Schneier et al., 2009).  Activation of the ACC has been found in the 
phenomenon of pupil dilatation and, by extension, eye contact (Pissiota et al., 2003; 
Critchley et al., 2005), which may explain lower volumes in this brain region of SAD 
patients, who display gaze avoidance behaviour. 
 
A number of studies have found functional activation differences in the prefrontal 
cortex of patients with SAD (Stein, Goldin et al., 2002; Amir et al., 2005; 
Lorberbaum et al., 2004; Straube et al., 2005, Phan et al., 2006; Goldin et al., 2009; 
Freitas-Ferrari et al., 2010; Blair et al., 2011). The finding of decreased left and right 
dorsolateral prefrontal cortical (DLPFC) volume is thus in line with such findings. 
While some researchers, such as Brühl et al. (2013), found increases in this brain 
region rather than decreases, finding differences in this region in either direction 
points to altered neural functioning in the prefrontal cortex in SAD. 
 
A medium effect size was observed for differences in the left and right DLPFC of 
HCs and SAD patients, with SAD patients having less volume. Decreased frontal 
lobe volume or thickness has been implicated in problematic emotional regulation 
(Etkin et al., 2011; Liao et al., 2011; Syal et al., 2012). The DLPFC has been 
implicated emotional, executive and attentional regulation, along with the ACC and 
parietal lobe (Diekhof, Geier, Falkai & Gruber, 2011; Etkin, Prater, Schatzberg, 
Menon & Greicius, 2009; Herwig et al., 2007; Kalisch, 2009; Oschner, Bunge, Gross 
& Gabrieli, 2002; Ochsner, Silvers, & Buhle, 2012). It has also been implicated in the 
experiences of moral transgressions and social transgressions in front of an audience 
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(Finger et al., 2006). Studies that have found increased volumes in this area (e.g. 
Brühl et al., 2013), suggest that this is due to hyperactive neural circuitry when 
processing emotional stimuli and as well as dysregulation in attentional networks 
(Sylvester et al., 2012). Studies have found reduced structural connections in the 
DLPFC (Baur et al., 2011, 2013; Phan et al., 2009), as well as disturbed connectivity 
(Hahn et al., 2011; Liao et al., 2011; Prater et al., 2013). These findings may explain 
some of the altered affective and cognitive processing in SAD patients. Furthermore, 
the DLPFC is part of the frontal cortex, which is closely connected to the 
orbitofrontal cortex, thalamus and hippocampus (Stein et al., 2000), in which 
differences in SAD patients have been found. This possibly suggests altered 
functional networks in the pathogenesis of the disorder.   
 
Again, a medium effect was observed for higher right amygdala volume in HCs when 
compared to SAD patients. Structural and functional amygdala changes have been 
previously found in the context of SAD (Etkin & Wager, 2007; Freitas-Ferrari et al., 
2010; Hattingh, 2011; Hattingh et al., 2013; Irle et al., 2010;  Phan et al., 2006; Stein, 
Goldin et al., 2002; Straube et al., 2005; Syal et al., 2012). The amygdala is thought 
to be form part of the brain’s emotional circuitry, and is particularly involved in fear 
conditioning (LeDoux, 1998; Morris et al., 1998; Schneier, Kent, Star & Hirsch, 
2007). Studies investigating gaze have also found differences in the amygdala in 
relation to altered gaze behaviour (Dumas et al., 2013; Spezio et al., 2007). 
Furthermore, studies investigating the neural circuitry of social emotions have also 
found alterations in amygdala activation (Berthoz et al. 2006; Britton et al., 2006; 
Eslinger et al., 2002; Moll, de Oliveira-Souza, Bramati et al., 2002; Moll, de Oliveira-
Souza). The amygdala is clearly an integral part of emotion and fear circuitry, which 
are thought to be central to SAD pathology. Thus, it is not surprising that a moderate 
effect was demonstrated in the current research for differences between SAD and 
HCs in the amygdala. 
 
Once age, education and total grey matter variables were taken into account in a 
regression analysis, statistically significant greater volumes in the left occipital 
cortex, left ACC and right inferior parietal lobe were found in HCs compared to SAD 
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patients (uncorrected peak values). However, the possible differences observed 
originally in the amygdala, right ACC and DLPFC bilaterally did not surface once 
variables of non-interest were included in the model. This suggests that those 
differences could be explained by differences in total grey matter volume, and even 
possibly to the demographic differences of age and education. Decreases in the right 
inferior parietal cortex are in line with the findings of Syal et al. (2012) and Talati et 
al. (2013). The parietal cortex has been implicated in empathic social behaviour 
(Carr, Iacoboni, Dubeau, Mazziotta & Lenzi, 2003; Rizzolatti & Craighero, 2004) 
and is decreased in socially debilitating disorders, such as autism spectrum disorder 
(Hadjikhani, Joseph, Snyder & Tager-Flusberg, 2006). Decreases in the left 
occipital cortex may be explained by the role of this area in the experience of 
embarrassment (Takahashi et al., 2004). It has been suggested that the occipital cortex 
undergoes increased activation to stimuli that are rich in emotional content, or that 
demand increased attention (Phan, Wagner, Taylor & Liberzon, 2002; Takahashi et 
al., 2004). It is thought that the cortex modulates sensory processes that involve the 
amygdala (Emery & Amaral, 2000). Decreases in this region may suggest decreased 
efficacy of this processing capacity. However, the results obtained when correcting 
for age, education and total grey matter should be interpreted with caution, given that 
they are significant at the peak and not cluster level. 
 
Structural differences predicted by symptom severity, blushing propensity and gaze 
avoidance 
Major Findings 
While differences in brain volumes between SAD patients and HCs are of value, the 
focus of this research is on how brain volume differences correlate with cardinal 
symptoms of the disorder, specifically blushing and gaze fear and avoidance. Severity 
of blushing and gaze fear and avoidance were found to be associated with  brain 
volume differences in the cerebellum, left inferior parietal lobe and right occipital 
lobe at the cluster level. While further differences were found in other regions, these 
were singificant only at the uncorrected peak level, and should not be given as much 
credence. 
 
68 
 
Taking both gaze and blushing symptoms (which are strongly collinear) into account, 
decreases in cerebellar volume were observed (significant at the uncorrected cluster 
level) with increased severity of both symptoms. Differences in cerebellar volume 
were also observed for an interaction between blushing and gaze symptoms, with 
increases in blushing severity and decreases in gaze fear and avoidance severity 
(significant at the corrected cluster level). This is in direct contrast to findings of 
increased cerebellar cortical thickness in SAD patients (Talati et al., 2013). However, 
it does implicate alterations in cerebellar functioning in SAD, despite the direction of 
the changes being contradictory. The cerebellum is thought to be involved in the 
control and coordination of motor activity (Brooks & Thach, 1981). However, it is 
now also thought that the cerebellum projects to non-motor areas of the cerebrum 
forming cerebral-cerebellar neural circuits, including the prefrontal, and parietal 
cortex (Strick, Dum & Fiez, 2009). The cerebellum may play a role in memory, 
attention, executive control, language, and learning (Strick et al., 2009). Thus, the 
possible differences found in the DLPFC and parietal lobe when directly comparing 
SAD and HC brain volumes in the current research may be related to these changes in 
the cerebellum. Furthermore, decreases in cerebellar volume and in the areas that 
comprise these circuits, may lead to deficits in these higher functions.  
 
Related to the observed volume decrease in the cerebellum, a decrease in pons 
volume was also suggested in this model (significant at the uncorrected cluster level). 
The pons serves as a major relay centre for information passing between the spinal 
cord and the cerebellum and cerebrum, as well as playing some role in balance, 
auditory processing and vision (Zillmer, Spiers & Culbertson, 2008). The cerebellar 
subdivisions project to midbrain areas of medulla and pons, which are responsible for 
regulation of autonomic responses. Such autonomic responses are raised in 
individuals with SAD (Baldacara, Borgio, Lacerda & Jackowski, 2008). Thus, 
abnormalities in the cerebellum may make individuals vulnerable to autonomic 
hyperactivity and thus anxiety.   
 
Increased severity of blushing was also associated with decreased volumes in the left 
inferior parietal lobe (cluster level uncorrected value). This decrease was also 
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predicted by the increases in blushing and gaze symptoms together (uncorrected peak 
value). The parietal lobe has been implicated in anxiety and it is thought to play a role 
in the hypervigilance that is present in anxious states (Davidson, 1998; Davidson, 
Abercrombie, Nitschke & Putnam, 1999). This may be why Syal et al. (2012) and 
Talati et al. (2013) found alterations in this region between SAD and HCs. Decreases 
in this region in association with increased blushing severity indicate a possible 
relationship between alterations in the parietal lobe and blushing propensity, as a 
specific symptom. That increases in gaze symptom severity alone did not predict this 
structural difference, suggests that blushing is more likely to be responsible for the 
observed changes. It is possible that the blush response may be interconnected with 
hypervigilance, and may be involved in a positive feedback mechanism with anxiety, 
in that anxiety triggers blushing, which triggers anxiety and so forth. 
 
Increased blushing severity was also associated with decreased volumes in left 
occipital cortex (uncorrected peak level) of SAD patients compared to controls. A 
similar finding was found for increased gaze symptom severity, but in the right 
occipital lobe (uncorrected cluster level). The occipital cortex has been implicated in 
the experience and evaluation of social transgressions, which may point to alterations 
in the emotional experience and cognitive processing of social stimuli in SAD 
patients compared to HCs. Altered activation of visual attention areas (Dumas et al., 
2013) and enhanced visual cortical responses (McTeague et al., 2011) have been 
observed in SAD, which is in line with the current findings. As previously discussed, 
decreases in the occipital cortex volume was demonstrated earlier in the current 
research when SAD and HCs were compared, accounting for symptom severity 
overall, but before taking the specific symptoms of blushing and gaze into account. 
The emergence of the occipital cortex in multiple models reinforces the hypothesis 
that this structure is important in mediating SAD and its characteristic symptoms. The 
significance of the right occipital lobe differences at the cluster level indicates the 
strength of this finding.  
 
Minor findings 
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While the associations found between blushing and gaze symptoms and the 
cerebellum, left inferior pareital love and right occipital lobe were the most robust, 
additional differences were found by the regression models and contrasts. However, 
these differences were not significant at the cluster level, and are therefore discussed 
here bearing that in mind. Of particular interest in these minor findings is the 
suggestion that increases in blushing severity were associated with increases in 
brainstem volume, because of the likely relationship between blushing and autonomic 
processes originating from the brainstem. 
 
Increased severity of blushing was associated with increased volumes in the 
brainstem (uncorrected peak value). Increased brainstem volume was also found for 
increased blushing and gaze fear and avoidance symptoms together (uncorrected peak 
value), further reinforcing the importance of the brainstem in blushing, and possibly 
in the symptoms as a cluster. However, brainstem volume changes were not predicted 
by increases in gaze symptom severity, suggesting that blushing propensity is most 
likely a major contributor to differences observed in this brain region. 
 
The brainstem plays a role in the autonomic processing, and while it has not yet been 
confirmed by MRI research, it is likely that the physiological elicitation of blushing 
may involve the brainstem vasomotor centres, in addition to central control centres, 
and peripheral dilatation mechanisms (Wilkins, 1983). An increase in the volume of 
this area in individuals with high blushing scores lends support to the idea that 
individuals suffering from SAD and blushing complaints may physically blush more 
than HCs, as found by Voncken and Bögels (2008), rather than just subjectively 
perceiving increased blushing or being more aware of their blushing, as suggested by 
some researchers in the field (Mulkens et al., 1997; Mulkens et al., 1999).   
 
Increases in gaze symptom severity predicted decreases in the volume of the right 
posterior cingulate cortex (PCC; uncorrected peak level) and right fusiform gyrus 
(uncorrected peak level) of SAD patients. Decreases in the fusiform gyrus of SAD 
patients were also found by Syal et al. (2012) and the fusiform gyrus has been 
implicated in altered gaze behaviour in SAD patients (Mueller et al., 2009; Fusar-Poli 
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et al., 2009), except that increased activation in this region was found.  Contrastingly, 
increased thickness in the fusiform gyrus has been found by Talati et al. (2013), while 
altered regulation of this region has been found in SAD patients (Etkin & Wager, 
2007; Gentili et al., 2008). The fusiform gyrus is part of the parahippocampal cortex 
and has been found to be involved in processing facial expression and facial 
recognition (Straube, Kolassa, Glauer, Mentzel & Miltner, 2004; Fairhall & Ishai, 
2007; Gentili et al., 2008). Decreases in this region may indicate less facial 
expression processing during social situations in SAD patients than in HCs. It is 
plausible that this may be because increased gaze avoidance reduces the amount of 
time that an individual focuses on facial cues. Altered activation in the PCC has been 
implicated in the experience of social emotions, social capacity and the ability to self-
reflect and make inferences about others (Britton et al., 2006; Johnson et al., 2002; 
Ochsner et al., 2002).  
 
When taking overall symptom severity (as measured by the LSAS) as a predictor, 
larger volumes were observed in SAD patients in several cortical areas, namely the 
left premotor cortex, right hippocampus, and left orbitofrontal cortex (uncorrected 
peak values). Decreased volumes were found in the right superior temporal cortex 
(uncorrected peak values). These findings are consistent with research that found 
decreases in the volume of (Syal et al., 2012; Talati et al., 2013) and altered activation 
in (Etkin & Wager, 2007; Gentili et al., 2008; Hattingh et al., 2013) the temporal 
cortex, as well as increases in the hippocampal area (Hattingh, 2011).  
 
These regions have been implicated in social and emotional processing (Carr et al., 
2003; Syal et al., 2012). The hippocampus has been specifically implicated in 
retrieval of socially relevant memories (Strange, Fletcher, Henson, Friston, & Dolan, 
1999). The temporal lobes are thought to be involved in emotional and social 
processing, as demonstrated from animal temporal lobe lesion experiments showing 
decreased social signalling (Franzen & Myers, 1973), facial processing problems 
(Snowden et al., 2003; Snowden, Thompson & Neary, 2004), perception of emotional 
faces (Fusar-Poli et al., 2009), and dementia resulting in social dysfunction 
(Thompson, Patterson & Hodges, 2003) when the temporal lobes were ablated. Thus, 
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decreases in the temporal cortex in SAD patients may explain problems in processing 
social emotional stimuli. The temporal lobe is integrally connected to the amygdala 
and the orbitofrontal cortex, which are both involved in emotional processing (Carr et 
al., 2003), and the right temporal cortex has been shown to be closely involved with 
social memory and emotion (Olson, Plotzker & Ezzyat, 2007).  Thus, increased 
symptom severity has implications for increasingly problematic social and emotional 
cognition, and that this increasing severity may be structurally reflected in the brain. 
 
Summary 
In the current research, the results that were significant at the corrected cluster level, 
followed by those that were significant at the uncorrected cluster level, should be 
regarded as more reliable than the uncorrected results. While uncorrected peak level 
results were discussed here, it is acknowledged that this was done for interest, given 
the exploratory nature of this research. Such results should not be regarded as robust 
findings, but rather as areas that have potential as areas of interest in future research. 
Thus, decreases in the cerebellum in relation to increased blushing propensity and 
gaze fear and avoidance together, decreases in the inferior parietal lobe with 
increased blushing, and decreases in the right occipital lobe with increased gaze 
anxiety and avoidance, should be regarded as the overarching picture from this 
analysis of specific SAD symptoms in relation to structural brain differences.  
However, while brainstem differences were significantly associated with blushing 
only at the uncorrected peak level, this may be an important region of future interest, 
given its likely role in autonomic processes. These differences lend further support to 
the notion that the aberrant affective and cognitive processing of SAD may be partly 
determined by altered brain structure. 
 
Further considerations 
The regions where neuroanatomical differences were found in the current research 
have been implicated in emotional processing circuitry. Social and emotional 
neurological processing is thought to involve the frontal, temporal, pre-motor, motor 
cortices as well as the limbic system (including the hippocampus and amygdala) of 
humans (Shin et al., 2010). Interestingly, no significant structural differences were 
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found in the amygdala or insula of SAD patients in any of the current analyses (apart 
from the medium effect size yet not significant difference observed in the right 
amygdala). This is contrary to the significant differences found by a number of 
researchers in the context of SAD (Stein, Goldin et al., 2002; Straube et al., 2005; 
Phan et al., 2006; Etkin & Wager, 2007; Freitas-Ferrari et al., 2010; Irle et al., 2010; 
Hattingh, 2011; Syal et al., 2012; Hattingh et al., 2013) and gaze pathology (Spezio et 
al., 2007; Dumas et al., 2013). However, the findings of the current research are in 
line with the findings of Syal et al., (2012), who also found no changes in the 
amygdala. Given that increased effort may be required by higher centres to control 
more basal structures when exposed to emotional stimuli (Sladky et al., 2012), the 
structural changes may be more evident in the higher centres. Syal et al. (2012) also 
note that the other regions in which they found differences (many similar to those 
found in the current research), are strongly interconnected with the amygdala, 
suggesting that such networks could underlie social threat processing networks. 
However, this is speculative, and highlights the need for further research into the role 
of the amygdala in relation to SAD symptom severity. 
 
The reasons for contrary findings between several studies, including the current 
research, regarding the direction of brain volume changes (i.e. some studies finding 
increases where others find decreases), may be multiple. Firstly, research into the 
neurobiology of SAD has made use of a variety of methods, including functional and 
structural imaging. Even between structural imaging studies, methods have been 
heterogeneous including cortical thickness reconstruction (e.g. Freesurfer analyses, as 
done by Brühl et al., 2013 and Hattingh, 2011) and volume calculations (e.g. manual 
tracings and VBM as done by Fusar-Poli et al., 2009). This problem within the field 
makes it difficult to compare the current study, which used VBM methodology, to 
other studies that used different methods. Secondly, the relationship between cortical 
thickness and function is unclear. In general, decreased volume is thought to be 
related to reduced function, while increased thickness is thought to related to 
increased utilisation (Brühl et al., 2013). Cortical volume increases observed in SAD 
patients suggest compensatory increases resulting from increased efforts to regulate 
aberrant emotional processing. However, nothing more than correlation between 
structure and function can be assumed. It is thought that cortical thickness is 
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determined by neuronal density, neuronal numbers, neuron size, glial cell number and 
size, myelination, vasculature, related to motor or intellectual exercise (Frick et al., 
2013). Furthermore, this between-study variability regarding brain regions implicated 
in SAD suggests that a number of neural circuits may be implicated in SAD 
pathology. Any number of these factors may be responsible for structural differences 
observed between individuals.  
 
Limitations  
Limitations of this research include a small sample size, missing data, the use of self-
report measures, between-group differences in average education level, not including 
other possible variables of non-interest in regression analyses, uncorrected peak level 
results, and not directly eliciting blushing and gaze avoidance in participants to 
determine real-time neural correlates.  
 
The small sample size (n = 18) limits the relevance of these findings to the wider 
population, and also reduces the strength of the findings. However, this sample size is 
generally considered acceptable when compared to other research in the field. This 
was not different from many neuroimaging studies, which have similarly low samples 
sizes (e.g. Adams et al., 2012; Blair et al., 2011; Liao et al., 2011; Schneier et al., 
2011). These low numbers are most likely due to the difficulty in sourcing patients 
and the labour intensity of the scanning procedure. However, in the current research, 
the missing data for several participants further reduced the sample size to less than 
hoped, so that it was less than in many of the neuroimaging studies (although some, 
such as Schneier et al., 2009, had similarly low numbers). All possible effort was 
made to obtain the missing data from participants, the data was not forthcoming. This 
affected both the results obtained as well as the analyses that were run. This sample 
size affected the regressions that were run, because it was impossible to run within 
group analyses due to low numbers. Instead, both SAD and HCs were included in a 
between group analyses. However, this research is preliminary and exploratory, so 
that results obtained here can be used to inform research that may follow in the 
future. 
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Ideally, all the participants would each have completed the full set of LSAS, BPS and 
Gaze scales and data would not have been missing. However, participants’ response 
and extent of participation was entirely voluntary so not everyone who participated in 
the scans decided to complete the tests, despite a number of concerted attempts to 
obtain this information. All data collected were included, leading to uneven group 
size for some measures, rather than omitting participants with incomplete data. This 
prevented reducing the sample size too greatly, allowing for some analyses to have a 
greater number of data points. This may, in part, be why some results with medium to 
large effect sizes and large t values were not significant. Furthermore, only some 
results were significant at the cluster level, making the strength of the findings with 
uncorrected peak values limited. The findings that were significant at the uncorrected 
and corrected cluster level are to be considered to be stronger than the uncorrected 
peak values.  
 
Using self-report measures for determining the severity of the symptoms of interest 
(blushing and gaze fear and avoidance) is limiting in that data may be subject to 
social desirability bias, response set, recall bias and flaws of subjectivity and 
introspection (Rosenthal & Rosnow, 2008). Using alternative measures such as 
physiological recording of blush and sympathetic response (e.g. Voncken & Bögels, 
2008) and eye-tracking (e.g. Horley et al., 2003; 2004; Moukheiber et al., 2010; 
Weister et al., 2009) would more objectively determine the degree of severity of these 
symptoms, however these would be time-consuming and costly to produce, and 
would also require the construction of simulated scenarios that would elicit these 
behaviours. These may be subject to the limitations associated with creating artificial 
scenarios. Furthermore, the self-report measures used in this research have been 
shown to be both reliable and valid for determining these symptoms in individuals 
(Baker et al., 2002; Langer et al., 2013; Leary & Meadows, 1991; Leibowitz, 1987; 
Mulkens et al., 1999; Schneier et al., 2011).  
 
Regarding variables of non-interest, it can be argued that there are other factors that 
may have bearing on brain structure, such as sex of participants, should have been 
included in the analysis. However, it was thought that age, education and total matter 
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volume would be adequate for the purposes of this study, because the sample size was 
not large enough to include sex. These factors are the most commonly associated with 
global brain volume variance in any population.  Thus, we wanted to isolate this 
variance, so that the remaining variances in brain volume observed could be more 
strongly associated with blushing, gaze and anxiety scores. This would not have been 
possible to do with more variables given the limited sample size. Thus, this 
shortcoming should be kept in mind for future analyses. 
 
As noted earlier, a number of the regression and contrast model findings were not 
significant at the cluster level and were observed, instead, at the uncorrected peak 
level. Thus, these particular results cannot be given same weight as the results that 
were significant at the cluster (corrected or uncorrected) level. 
 
This study was a structural MRI protocol that looked at how differences in SAD and 
HC brain areas could be predicted by high blushing and gaze scores. Like many MRI 
studies, the resulting differences are correlations and causation (in either direction) 
cannot be determined. Furthermore, a functional MRI study designed to elicit 
blushing and gaze fear and avoidance would go further to determine the brain areas 
associated with these symptoms in both HCs and SAD patients. However, a structural 
study can serve as an initial phase of a functional study, providing results that can 
contribute to hypotheses or determine research focus of a future functional study. It is 
important to understand both structural and functional biology when investigating a 
neurobiological disorder of this kind. 
 
Recommendations for Future Research 
Further research on this topic could include repeating the analysis with a larger and 
more complete data set. Meeting minimum sample size requirements as indicated by 
post-hoc power analyses would help to establish whether areas of interest indicated 
by medium to large effect sizes are in fact signals rather than noise. A larger sample 
size will allow for within group regression analyses to be run. It may also be worth 
exploring the possible effects of reduced symptom severity and treatment options on 
brain structure and function. Given the exploratory nature of this research, the brain 
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regions that emerged in the analysis as areas of difference between SAD patients and 
HCs could be used to generate hypotheses for future research, guiding focus on 
particular areas of interest. Furthermore, while the symptoms of blushing propensity 
and gaze fear and avoidance have a strong relationship with SAD, it may be worth 
investigating other symptoms considered to be associated with SAD, including other 
physical symptoms (such as panic, stuttering, sweating and trembling), as well as 
other behavioural and cognitive symptoms. 
 
More research into structural and functional neurobiology of SAD, especially with a 
focus on cardinal symptoms in patients, is needed. The research into blushing and 
gaze is very limited, and even more so when considered in the context of SAD. It 
remains a challenge to image directly elicited behaviour in an MRI scanner. A 
protocol for the direct elicitation of blushing that is compatible with the scanner has 
been developed by van der Merwe (2008), and was piloted with HCs in 2010 
(unpublished work), but data from the use of this protocol has yet to be successfully 
obtained. Using this protocol for both HCs and SAD patient would shed light on the 
neural correlates of blushing and the differences between normal and pathological 
blushing. As far as I am aware, a protocol for the direct elicitation of gaze avoidance 
has not yet been established. However, by developing and using a functional MRI 
protocol that could directly image gaze avoidance, this could be used in a similar way 
to further understanding of the functional neural circuitry involved in gaze behaviour, 
and how SAD patients and HCs differ from each other. This could complement and 
build on the structural findings of this research.  Genetic studies of both blushing and 
gaze may also be worth exploring, given the multifactorial nature of these symptoms 
and of SAD. The current study serves as a foundation for such research.  
 
 
 
Conclusion 
In the current research, I found that increased blushing and increased gaze fear and 
avoidance are highly associated with a diagnosis of SAD, while also being associated 
with structural neuroanatomical differences in individuals with the disorder. It was 
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also found that these symptoms correlated highly with general symptom severity, and 
with each other, suggesting that they are both a prominent component of SAD 
pathology, and may likely to occur together. This is consistent with previous research 
that has linked blushing and gaze avoidance behaviour closely to SAD, as well as 
research that neurobiological factors are likely to play an important role in the 
aetiology of SAD.  
 
Regarding structural neurobiological underpinnings of SAD, my findings suggest that 
there are significant volume differences between SAD and HCs in the regions of the 
left occipital cortex, left anterior cingulate and right inferior parietal lobe for SAD in 
general (lesser volumes in SAD patients), as well as differences in the left premotor 
cortex, left orbitofrontal cortex (both increased in SAD), and right superior temporal 
cortex (decreased in SAD) with increasing symptom severity. Medium effects were 
observed for differences in the ACC and DPLFC and amygdala between SAD 
patients and HCs, as well as total grey matter volume (strong effect) but these were 
not significant.  
 
Furthermore, my findings indicate that the symptoms of blushing propensity and gaze 
avoidance behaviour (including anxiety about gaze), are correlated with structural 
neuroanatomical differences. Increased blushing propensity corresponds to increases 
in the brainstem, and decreases in the inferior parietal lobe and left occipital cortex. 
Increases in gaze symptom severity corresponded to decreases in the posterior 
cingulated cortex, occipital lobe and fusiform gyrus. Blushing and gaze together were 
found to relate to increased volumes in the brainstem, and decreases in the 
pons/cerebellum, parietal lobe.  
 
Taking these results together, SAD patients and HCs were found to have significantly 
different brain structure in the areas associated with emotional regulation and 
cognitive appraisal. With increasing symptom severity SAD patients had increased 
brain volume in areas responsible for social emotional processing, possibly related to 
hypervigilance and altered social cognition. Decreases in the temporal lobe for SAD 
patients may explain problems processing social stimuli. Brainstem increases with 
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increased blushing propensity is suggestive of increased sympathetic activation and 
enhanced blush response, while decreases in the parietal and occipital lobes suggest 
alterations in the evaluation of social transgressions and emotional processing. 
Decreases in the cingulate cortex, occipital lobe and fusiform gyrus with increased 
aze fear and avoidance severity suggest changes in social emotion processing and 
capacity for reflection.  
 
However, out of all these results, those significant at the cluster level were decreases 
in the left inferior parietal lobe with increased blushing symptom severity, decreases 
in the right occipital cortex with increased gaze symptoms severity, decreases in the 
pons/cerebellum and right cerebellum with collinear increases in blushing and gaze 
severity (significant at the uncorrected cluster level), and in the cerebellum bilaterally 
for increased blushing and decreased gaze severity (significant at the corrected FWE 
cluster level). Thus, these results should be regarded as being more robust than the 
others. These regions imply alterations in higher functions that are modulated by the 
cerebellum, altered emotional and cognitive processing of social stimuli, and 
hypervigilance (which has implications for anxiety). These regions can be considered 
areas of interest for studies that further explore these symptoms in relation to SAD. 
 
Currently, gold standard treatment available for pathological blushing involves 
drastic surgery that is prone to side-effects, and research into the treatment for gaze 
avoidance is still in its infancy. While treatment for SAD as a disorder is well 
established, and may have some effect on the specific symptoms of blushing and gaze 
avoidance, more targeted treatments would be desirable in individuals with these as 
primary complaints. Furthermore, pharmacotherapy of blushing has been shown to be 
transiently successful at best. Thus, developing a sound understanding of the 
neurobiology of blushing and gaze behaviour in relation to SAD, in accordance with 
RDoC, may assist in developing targeted treatment and improve patient management.  
 
In conclusion, differences in brain volumes pertaining to blushing and gaze avoidance 
behaviour in SAD patients may be a contributing factor or a consequence of these 
core symptoms, and a potential biomarker for SAD.  Future studies could build on 
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this preliminary research with increased sample sizes, and determine the possible 
effects of reduced symptom severity and treatment options on brain structure and 
function. Most importantly, an investigation of the genetic underpinnings and 
functional neural correlates of blushing and gaze avoidance behaviour may enhance 
our understanding of the complex aetiology of these cardinal SAD symptoms, thereby 
improving our understanding of SAD as a psychiatric disorder and facilitating better 
patient care and management. 
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APPENDIX A 
LIEBOWITZ SOCIAL ANXIETY SCALE 
Name:__________________________Date:_______________________________ 
 
Indicate how often you feel fearful or anxious in each of the following situations and how 
often you avoid each of them using the scales below.  Circle the most appropriate answer. 
 
Fear or Anxiety:     Avoidance 
0 = None      0 = Never (0%) 
1 = Mild      1 = Occasionally (1-33%) 
2= Moderate      2 = Often (33-67%) 
3=Severe      3 = Usually (67-100%) 
 
1.  Telephoning in public 
Fear or Anxiety  
0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
2. Participating in small groups 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
3. Acting, performing or giving a talk in front of an audience. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
4. Eating in public places 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
5.  Drinking with others in public places. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
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6.  Talking to people in authority. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
7.  Going to a party 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
8.  Working while being observed. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
9.  Writing while being observed. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
10.  Calling someone you don’t know very well. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
11. Talking with people you don’t know very well. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
12.  Meeting strangers. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
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13.  Urination in a public bathroom. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
14.  Entering a room when others are already seated. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
15.  Being the centre of attention. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
16.  Speaking up at a meeting. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
17.  Taking a test. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
18.  Expressing a disagreement or disapproval to people you don’t know very well. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
19.  Looking at people you don’t know very well in the eyes. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
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20.  Giving a report to a group. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
21.  Trying to pick up someone. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
22.  Returning goods to a store. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
23.  Giving a party. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
 
24. Resisting a high pressure salesperson. 
Fear or Anxiety 0   1   2   3 
            None            Mild          Moderate                    Severe 
 
Avoidance  0   1   2   3  
   Never                  Occasionally                    Often                        Usually 
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APPENDIX B 
 
BLUSHING PROPENSITY SCALE 
Name:_____________________________ Date:_______________________________ 
 
Indicate how often you feel yourself blush in each of the following situations using the scale 
below.  Circle the most appropriate answer. 
 
 1 = I NEVER feel myself blush in this situation. 
 2 = I RARELY feel myself blush in this situation. 
 3 = I OCCASIONALLY feel myself blush in this situation. 
 4 = I OFTEN feel myself blush in this situation. 
 5 = I ALWAYS feel myself blush in this situation. 
 
 1.  When a teacher calls on me in class 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
 2.  When talking to someone about a personal topic 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
3.  When I'm embarrassed 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
4.  When I'm introduced to someone I don't know 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
5.  When I've been caught doing something improper or shameful 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
 6.  When I'm the center of attention 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
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7.  When a group of people sings "Happy Birthday" to me 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
8. When I'm around someone I want to impress 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
 9.  When talking to a teacher or boss 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
10.  When speaking in front of a group of people 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
11.  When someone looks me right in the eye 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
12. When someone pays me a compliment 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
13. When I've looked stupid or incompetent in front of others 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
 
14. When I'm talking to a member of the other sex 
 
1   2   3   4   5 
Never   Rarely     Occasionally         Often        Always 
 
APPENDIX C 
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GAZE ANXIETY RATING SCALE 
 
The following questions ask if you feel anxiety making eye contact and avoid eye contact in 
various situations.  Base your ratings on the way you have felt and behaved in the past week.  
If you have not been in the situation recently, please you imagine your expected anxiety and 
avoidance of eye contact in the situation.   
 
Note: Do not rate anxiety related to just being in the situation.  Rate anxiety and avoidance of 
making eye contact while in the situation.   
 ANXIETY MAKING EYE 
CONTACT 
0 No anxiety  
1 A little anxiety 
2 Moderate anxiety clinic 
3 A lot of anxiety 
 
AVOIDANCE OF EYE 
CONTACT 
0 No avoidance 
1 Avoid a little 
2 Avoid moderately 
3 Avoid a lot 
1. Giving a speech _____ _____ 
2. Speaking to a group of 
people at a party 
_____ _____ 
3. Speaking up at a 
meeting 
_____ _____ 
4. Speaking in a 
discussion with a few 
people 
_____ _____ 
5. Dealing with a cashier 
when buying something 
_____ _____ 
6. Being introduced _____ _____ 
7. Greeting an 
acquaintance passing by 
on the street 
_____ _____ 
8. Speaking with someone 
you don’t know well 
_____ _____ 
9. Speaking to someone 
you find attractive 
_____ _____ 
10. Inviting someone you 
don’t know well on a 
date or other social 
activity. 
_____ _____ 
11. Feeling close to 
someone you love 
_____ _____ 
12. Discussing the quality 
of your work with a 
boss or a teacher. 
_____ _____ 
13. Having a routine talk 
with a close family 
member 
_____ _____ 
14. Listening while a 
person speaks to you, in 
general 
_____ _____ 
108 
 
15. Speaking while a 
person listens to you, in 
general 
_____ _____ 
16. Expressing a 
disagreement 
_____ _____ 
17. Receiving a 
compliment 
_____ _____ 
TOTAL SCORE (Sum 
of items 1-17): 
       _____ +            _____ =  _____ 
 Grand Total 
Descriptive Items 
 
Please rate the additional items on the following scale: 
0 Not at all 
1 A little  
2 Moderately 
3 A lot 
 
18.       I avoid eye contact because it make me anxious 
19.       I avoid eye contact only because it interferes with my concentration (not due to 
anxiety) 
20.       I feel self-conscious when I make eye contact. 
21.       I am concerned that I stare too much into others’ eyes. 
22.       I have difficulty deciding how much eye contact is best. 
23.       Making eye contact is important for my social and work relationships 
 
(If you have no anxiety about eye contact, check here ____ and skip items below.) 
Complete the following items if you have some anxiety about eye contact or avoidance of eye 
contact 
 
 
 
APPENDIX D 
 
 
Analysis of brain volume differences with SAD n= 16 and HC n=10 
 
 
Table 6 
Descriptive statistics (mean, standard deviation and effect size) and independent 
sample t-tests of SAD patients and health controls for brain volumes (SAD n=16, 
HC=10 
Scale Scores 
SAD 
Mean (SD) 
HC 
Mean (SD) 
t p df 
Effect size 
(Cohen’s d) 
Total brain volumes       
Grey Matter (ml) 714(60) 760(56) 2.01 0.058 20 0.83 
White Matter (ml) 483(54) 502(52) 0.90 0.376 20 0.38 
CSF (ml) 557(199) 594(185) 0.48 0.637 20 0.20 
Total Intracranial volume (ml) 1754(251) 1856 (183) 1.20 0.242 23 0.47 
Grey matter volumes 
Left Insula (ml) 7.5(0.7) 7.7 (0.9) 0.664 0.516 16 0.30 
Right Insula (ml) 7.0(0.6) 7.2(0.9) 0.44 0.668 15 0.20 
Left ACC (ml) 6.2(0.7) 6.7(0.9) 1.51 0.150 15 0.68 
Right ACC (ml) 5.3(0.6) 5.7(0.8) 1.43 0.172 15 0.65 
Left Hippocampus (ml) 4(0.4) 4.1(0.4) 0.55 0.592 17 0.24 
Right Hippocampus (ml) 3.7(0.4) 3.8(0.4) 0.40 0.690 20 0.17 
Left Amygdala (ml) 1.06(0.11) 1.10(0.13) 0.88 0.391 17 0.38 
Right Amygdala (ml) 1.05(0.12) 1.11(0.14) 1.22 0.241 16 0.54 
Left DLPFC (ml) 11.5(1.3) 12.1(1.1) 1.37 0.185 22 0.61 
Right DLPFC (ml) 13.3(1.5) 14.3(1.8) 1.4 0.180 16 0.60 
 
